Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission file number 001-13489



(Exact name of registrant as specified in its Charter)

Delaware	52-2057472
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization	Identification No.)

100 E. Vine Street
Murfreesboro, TN 37130
(Address of principal executive offices)
(Zip Code)

(615) 890–2020
Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading

Symbols(s)

Name of each exchange on which

registered

Common, $0.01 par value

NHC

NYSE American

Indicate by check mark whether the registrant: (1) Has filed all reports required to be filed by Section 13 or 15(d), of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S–T (§ 232.405 of this chapter) during the preceding 12 months (or for such period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated filer ☒	Accelerated filer ☐

Non–accelerated filer ☐	Smaller reporting company ☐

	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as is defined in Rule 12b–2 of the Exchange Act). Yes ☐ No ☒

15,399,724 shares of common stock of the registrant were outstanding as of May 1, 2024.

Table of Contents

Table of Contents

PART I. FINANCIAL INFORMATION
		Page
Item 1.	Financial Statements	3

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	24

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36

Item 4.	Controls and Procedures	36

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	37

Item 1A	Risk Factors	37

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37

Item 3.	Defaults Upon Senior Securities	37

Item 4.	Mine Safety Disclosures	37

Item 5.	Other Information	37

Item 6.	Exhibits	38

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

	Three Months Ended March 31
	2024			2023

Revenues:
Net patient revenues	$	285,823		$	258,007
Other revenues		11,353			11,556
Net operating revenues		297,176			269,563

Cost and expenses:
Salaries, wages, and benefits		183,138			167,824
Other operating		77,429			71,489
Facility rent		10,348			10,092
Depreciation and amortization		10,586			10,048
Interest		46			98
Total costs and expenses		281,547			259,551

Income from operations		15,629			10,012

Other income:
Non–operating income		5,685			4,323
Unrealized gains on marketable equity securities		14,399			1,386

Income before income taxes		35,713			15,721
Income tax provision		(9,462	)		(4,436	)
Net income		26,251			11,285
Net (income)/loss attributable to noncontrolling interest		(38	)		438

Net income attributable to National HealthCare Corporation	$	26,213		$	11,723

Earnings per share attributable to National HealthCare Corporation stockholders:
Basic	$	1.71		$	0.76
Diluted	$	1.69		$	0.76

Weighted average common shares outstanding:
Basic		15,350,240			15,337,423
Diluted		15,505,096			15,356,335

Dividends declared per common share	$	0.59		$	0.57

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Statements of Comprehensive Income

(unaudited – in thousands)

	Three Months Ended March 31
	2024			2023

Net income	$	26,251		$	11,285

Other comprehensive income/(loss):
Unrealized gains/(losses) on investments in marketable debt securities		(472	)		1,958
Reclassification adjustment for realized gains on sales of marketable debt securities		(10)			-
Income tax (expense)/benefit related to items of other comprehensive income		45			(279	)
Other comprehensive income/(loss), net of tax		(437	)		1,679

Net (income)/loss attributable to noncontrolling interest		(38	)		438

Comprehensive income attributable to National HealthCare Corporation	$	25,776		$	13,402

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Balance Sheets

(in thousands)

	March 31, 2024			December 31, 2023
	unaudited
Assets
Current Assets:
Cash and cash equivalents	$	93,982		$	107,076
Restricted cash and cash equivalents, current portion		26,010			17,725
Marketable equity securities		123,040			111,117
Marketable debt securities		484			5,427
Restricted marketable equity securities		29,616			26,779
Restricted marketable debt securities, current portion		4,790			12,822
Accounts receivable		125,664			108,545
Inventories		6,763			7,386
Prepaid expenses and other assets		6,750			8,855
Notes receivable		487			503
Total current assets		417,586			406,235

Property and Equipment:
Property and equipment, at cost		1,065,543			1,101,681
Accumulated depreciation and amortization		(576,845	)		(608,352	)
Net property and equipment		488,698			493,329

Other Assets:
Restricted cash and cash equivalents, less current portion		1,140			1,167
Restricted marketable debt securities, less current portion		119,042			109,478
Deposits and other assets		13,738			14,786
Operating lease right-of-use assets		87,356			94,201
Goodwill		168,295			168,295
Intangible assets		7,038			7,038
Investments in unconsolidated companies		16,747			16,267
Total other assets		413,356			411,232
Total assets	$	1,319,640		$	1,310,796

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Balance Sheets (continued)

(in thousands, except share and per share amounts)

	March 31, 2024			December 31, 2023
	unaudited
Liabilities and Stockholders’ Equity
Current Liabilities:
Trade accounts payable	$	20,697		$	19,194
Finance lease obligations, current portion		-			860
Operating lease liabilities, current portion		29,733			29,352
Accrued payroll		64,156			84,110
Amounts due to third party payors		19,988			18,369
Accrued risk reserves, current portion		30,800			30,549
Other current liabilities		24,302			22,991
Contract liabilities		7,667			-
Dividends payable		9,086			9,051
Total current liabilities		206,429			214,476

Operating lease liabilities, less current portion		56,004			63,175
Accrued risk reserves, less current portion		77,437			72,710
Refundable entrance fees		5,708			6,376
Deferred income taxes		19,639			17,200
Other noncurrent liabilities		27,909			26,379
Total liabilities		393,126			400,316

Equity:
Common stock, $.01 par value; 45,000,000 shares authorized; 15,399,724 and 15,350,661 shares, respectively, issued and outstanding		154			153
Capital in excess of par value		226,909			227,604
Retained earnings		704,726			687,599
Accumulated other comprehensive loss		(7,041	)		(6,604	)
Total National HealthCare Corporation stockholders’ equity		924,748			908,752
Noncontrolling interest		1,766			1,728
Total equity		926,514			910,480
Total liabilities and equity	$	1,319,640		$	1,310,796

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Statements of Cash Flows

(unaudited – in thousands)

	Three Months Ended March 31
	2024			2023
Cash Flows From Operating Activities:
Net income	$	26,251		$	11,285
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		10,586			10,048
Equity in earnings of unconsolidated investments		(67	)		(1,535	)
Unrealized gains on marketable equity securities		(14,399	)		(1,386	)
(Gains)/losses on sale of marketable securities		(344	)		492
Gain on sale of unconsolidated company		(1,024	)		-
Deferred income taxes		2,484			331
Stock–based compensation		793			639
Changes in operating assets and liabilities:
Accounts receivable		(17,119	)		(3,148	)
Inventories		623			142
Prepaid expenses and other assets		3,153			1,957
Operating lease obligations		55			(316	)
Trade accounts payable		1,503			(4,018	)
Accrued payroll		(19,954	)		(15,800	)
Amounts due to third party payors		1,619			48
Accrued risk reserves		4,978			3,157
Contract liabilities		7,667			-
Other current liabilities		1,311			5,407
Other noncurrent liabilities		1,530			6,554
Net cash provided by operating activities		9,646			13,857
Cash Flows From Investing Activities:
Purchases of property and equipment		(5,955	)		(6,640	)
Proceeds from sale of unconsolidated company		2,100			-
Investments in unconsolidated companies		(1,488	)		-
Collections of notes receivable		16			2
Purchases of marketable securities		(8,703	)		(10,281	)
Proceeds from sale of marketable securities		11,615			15,492
Net cash used in investing activities		(2,415	)		(1,427	)
Cash Flows From Financing Activities:
Principal payments under finance lease obligations		(860	)		(1,218	)
Dividends paid to common stockholders		(9,051	)		(8,748	)
Issuance of common stock		8,412			-
Repurchase of common shares		(9,900	)		(2,482	)
Entrance fee refunds		(668	)		(171	)
Net cash used in financing activities		(12,067	)		(12,619	)
Net Decrease in Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents		(4,836	)		(189	)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning of Period		125,968			74,865
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, End of Period	$	121,132		$	74,676

Balance Sheet Classifications:
Cash and cash equivalents	$	93,982		$	46,144
Restricted cash and cash equivalents		27,150			28,532
Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	$	121,132		$	74,676

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Interim Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share and per share amounts)

(unaudited)

For the three months ended March 31, 2024:

	Common Stock					Capital in Excess of			Retained			Accumulated Other Comprehensive			Non- controlling		Total Stockholders’
	Shares			Amount		Par Value			Earnings			Loss			Interest		Equity
Balance at January 1, 2024		15,350,661		$	153	$	227,604		$	687,599		$	(6,604	)	$	1,728	$	910,480
Net income		–			–		–			26,213			–			38		26,251
Other comprehensive loss		–			–		–			–			(437	)		–		(437	)
Stock–based compensation		–			–		793			–			–			–		793
Shares sold – options exercised		150,194			1		8,412			–			–			–		8,413
Repurchase of common shares		(101,131	)		–		(9,900	)		–			–			–		(9,900	)
Dividends declared to common stockholders ($0.59 per share)		–			–		–			(9,086	)		–			–		(9,086	)
Balance at March 31, 2024		15,399,724		$	154	$	226,909		$	704,726		$	(7,041	)	$	1,766		926,514

For the three months ended March 31, 2023:

	Common Stock					Capital in Excess of			Retained			Accumulated Other Comprehensive			Non- controlling			Total Stockholders’
	Shares			Amount		Par Value			Earnings			Income (Loss)			Interest			Equity
Balance at January 1, 2023		15,357,746		$	153	$	226,991		$	656,664		$	(9,532	)	$	3,238		$	877,514
Net income/(loss)		–			–		–			11,723			–			(438	)		11,285
Other comprehensive income		–			–		–			–			1,679			–			1,679
Stock–based compensation		–			–		639			–			–			–			639
Shares sold – options exercised		7,046			–		–			–			–			–			–
Repurchase of common shares		(44,349	)		–		(2,482	)		–			–			–			(2,482	)
Dividends declared to common stockholders ($0.57 per share)		–			–		–			(8,733	)		–			–			(8,733	)
Balance at March 31, 2023		15,320,443		$	153	$	225,148		$	659,654		$	(7,853	)	$	2,800			879,902

The accompanying notes to interim condensed consolidated financial statements are an integral part of these consolidated statements.

Table of Contents

NATIONAL HEALTHCARE CORPORATION

Notes to Interim Condensed Consolidated Financial Statements

March 31, 2024

(unaudited)

Note 1 – Description of Business

National HealthCare Corporation (“NHC” or the “Company”) is a leading provider of senior health care services. As of March 31, 2024, we operate or manage, through certain affiliates, 65 skilled nursing facilities with a total of 8,421 licensed beds, 24 assisted living facilities with 1,365 units, five independent living facilities, three behavioral health hospitals, 35 homecare agencies, and 30 hospice agencies. We operate specialized care units within certain of our healthcare centers such as Alzheimer's disease care units and sub-acute nursing units. In addition, we provide insurance services, management and accounting services, and we lease properties to operators of skilled nursing and assisted living facilities. We operate in 8 states and are located primarily in the southeastern United States.

Note 2 – Summary of Significant Accounting Policies

The listing below is not intended to be a comprehensive list of all our significant accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by U.S. generally accepted accounting principles (“GAAP”), with limited need for management’s judgment in their application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result. See our audited December 31, 2023 consolidated financial statements and notes thereto which contain accounting policies and other disclosures required by U.S. GAAP. Our audited December 31, 2023 consolidated financial statements are available at our web site: www.nhccare.com.

Basis of Presentation

The unaudited interim condensed consolidated financial statements to which these notes are attached include all normal, recurring adjustments which are necessary to fairly present the financial position, results of operations and cash flows of NHC. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by NHC. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to NHC and the noncontrolling interest in its consolidated statements of operations.

We assume that users of these interim financial statements have read or have access to the audited December 31, 2023 consolidated financial statements and that the adequacy of additional disclosure needed for a fair presentation, except in regard to material contingencies, may be determined in that context. Accordingly, footnotes and other disclosures which would substantially duplicate the disclosure contained in our most recent annual report to stockholders have been omitted. This interim financial information is not necessarily indicative of the results that may be expected for a full year for a variety of reasons.

Estimates and Assumptions

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and could cause our reported net income to vary significantly from period to period.

Net Patient Revenues and Accounts Receivable

Net patient revenues are derived from services rendered to patients for skilled and intermediate nursing, rehabilitation therapy, assisted living and independent living, home health care services, hospice services, and behavioral health services. Net patient revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient services. These amounts are due from patients, governmental programs, and other third-party payors, and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations.

The Company recognizes revenue as its performance obligations are completed. Routine services are treated as a single performance obligation satisfied over time as services are rendered. These routine services represent a bundle of services that are not capable of being distinct. The performance obligations are satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time when those services are rendered. Contract liabilities are recorded for payments the Company receives in which performance obligations have not been completed.

Table of Contents

The Company determines the transaction price based on established billing rates reduced by explicit price concessions provided to third party payors. Explicit price concessions are based on contractual agreements and historical experience. The Company considers the patient's ability and intent to pay the amount of consideration upon admission. Credit losses are recorded as bad debt expense, which is included as a component of other operating expenses in the interim condensed consolidated statements of operations. Bad debt expense was $2,471,000 and $1,811,000 for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, and December 31, 2023, the Company has recorded allowance for doubtful accounts of $9,174,000 and $8,054,000, respectively, as our best estimate of expected losses inherent in the accounts receivable balance.

Other Revenues

Other revenues include revenues from the provision of insurance services, management and accounting services to other long–term care providers, and rental income. Our insurance revenues consist of premiums that are generally paid in advance and then amortized into income over the policy period. We charge for management services based on a percentage of net revenues. We charge for accounting services based on a monthly fee or a fixed fee per bed of the healthcare center under contract. We record other revenues as the performance obligations are satisfied based on the terms of our contractual arrangements.

We recognize rental income based on the terms of our operating leases. Under certain of our leases, we receive variable rent, which is based on the increase in revenues of a lessee over a base year. We recognize variable rent annually or monthly, as applicable, when, based on the actual revenue of the lessee is earned.

Segment Reporting

In accordance with the provisions of Accounting Standards Codification ("ASC") 280, Segment Reporting, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services. The Company also reports an “all other” category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. See Note 6 for further disclosure of the Company’s operating segments.

Other Operating Expenses

Other operating expenses include the costs of care and services that we provide to the residents of our facilities and the costs of maintaining our facilities. Our primary patient care costs include drugs, medical supplies, purchased professional services, food, and professional liability insurance and licensing fees. The primary facility costs include utilities and property insurance.

General and Administrative Costs

With the Company being a healthcare provider, the majority of our expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its corporate office costs, excluding stock-based compensation, which were $6,164,000 and $5,653,000 for the three months ended March 31, 2024 and 2023, respectively.

Long-Term Leases

The Company’s lease portfolio primarily consists of operating real estate leases for certain skilled nursing facilities, assisted and independent living facilities, homecare and hospice offices, and pharmacy warehouses. The original terms of the leases typically range from two to fifteen years. Several of the real estate leases include renewal options which vary in length and may not include specific rent renewal amounts. We determine if an arrangement is a lease at inception of a contract. We determine the lease term by assuming exercise of renewal options that are reasonably certain.

The Company records right-of-use assets and liabilities for non-cancelable real estate operating leases with original or remaining lease terms in excess of one year. Leases with a lease term of 12 months or less at inception are not recorded and are expensed on a straight-line basis over the lease term. We recognize lease components and non-lease components together and not as separate parts of a lease for real estate leases.

Table of Contents

Operating lease right-of-use assets and liabilities are recorded at the present value of the lease payments over the lease term. The present value of the lease payments are discounted using the incremental borrowing rate associated with each lease. The variable components of the lease payment that fluctuate with the operations of a health facility are not included in determining the right-of-use assets and lease liabilities. Rather, these variable components are expensed as incurred.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided by the straight-line method over the expected useful lives of the assets estimated as follows: buildings and improvements, 20-40 years and equipment and furniture, 3-15 years. Leasehold improvements are amortized over periods that do not exceed the non-cancelable respective lease terms using the straight-line method.

Business Combinations

We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, Business Combinations. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. In determining the fair value of identifiable assets, we use various valuation techniques. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth, and discount rates.

Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is subject to an annual impairment test. We perform our annual goodwill impairment assessment on the first day of the fourth quarter. Tests are performed more frequently if events occur, or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.

The Company’s indefinite-lived intangible assets consist of trade names and certificates of need and licenses. The Company reviews indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.

Accrued Risk Reserves

We are self–insured for risks related to workers’ compensation and general and professional liability insurance. We have two wholly–owned limited purpose insurance companies that insure these risks. The accrued risk reserves include a liability for reported claims and estimates for incurred but unreported claims. Our policy is to engage an external, independent actuary to assist in estimating our exposure for claims obligations (for both asserted and unasserted claims). We reassess our accrued risk reserves on a quarterly basis.

Professional liability remains an area of particular concern to us. The long-term care industry has seen an increase in personal injury/wrongful death claims based on alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims could have a material adverse effect on our consolidated financial position, results of operations and cash flows. It is also possible that future events could cause us to make significant adjustments or revisions to these reserve estimates and cause our reported net income to vary significantly from period to period.

We are principally self-insured for incidents occurring in all centers owned or leased by us. The coverages include both primary policies and excess policies. In all years, settlements, if any, in excess of available insurance policy limits and our own reserves would be expensed by us.

Table of Contents

Continuing Care Contracts

We have one continuing care retirement center (“CCRC”) within our operations. Residents at this retirement center may enter into continuing care contracts with us. The contracts provide that 10% of the resident entry fee becomes non-refundable upon occupancy, and the remaining refundable portion of the entry fee is calculated using the lesser of the price at which the apartment is re-assigned or 90% of the original entry fee, plus 40% of any appreciation if the apartment value exceeds the original resident’s entry fee.

Non-refundable fees are included as a component of the transaction price and are amortized into revenue over the actuarily determined remaining life of the resident, which is the expected period of occupancy by the resident. We pay the refundable portion of our entry fees to residents when they relocate from our community and the apartment is re-occupied. Refundable entrance fees are not included as part of the transaction price and are classified as noncurrent liabilities in our consolidated balance sheets.

We also annually estimate the present value of the cost of future services and the use of facilities to be provided to the current CCRC residents and compare that amount with the balance of non-refundable deferred revenue from entrance fees received. If the present value of the cost of future services exceeds the related anticipated revenues, a liability is recorded with a corresponding charge to income. As of March 31, 2024, and December 31, 2023, we have recorded a future service obligation liability in the amount of $1,606,000. This obligation is reflected within other noncurrent liabilities in the interim condensed consolidated balance sheets.

Other Noncurrent Liabilities

Other noncurrent liabilities include reserves primarily related to various uncertain income tax positions, deferred revenue, and obligations to provide future services to our CCRC residents. Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation (“National”) and the non-refundable portion (10%) of CCRC entrance fees being amortized over the remaining life expectancies of the residents.

Other noncurrent liabilities also include funds received related to the Employee Retention Credit ("ERC"), a refundable tax credit for businesses that sustained a partial suspension of operations limiting commerce due to COVID-19 or had significant declines in gross receipts during 2020 and 2021.

Noncontrolling Interest

The noncontrolling interest in a subsidiary is presented within total equity in the Company's interim condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its interim condensed consolidated statements of operations. The Company’s earnings per share is calculated based on net income attributable to NHC’s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of the subsidiary earnings, contributions, and distributions.

Variable Interest Entities

We have equity interests in unconsolidated limited liability companies that operate various post-acute and senior healthcare businesses. We analyze our investments in these limited liability companies to determine if the company is considered a variable interest entity (“VIE”) and would require consolidation. To the extent that we own interests in a VIE and we (i) have the power to direct the activities of the VIE and (ii) have the obligation or rights to absorb the VIE's losses or receive its benefits, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary.

The Company's maximum exposure to losses in its investments in unconsolidated VIEs cannot be quantified and may or may not be limited to its investment in the unconsolidated VIE. The investments in unconsolidated VIEs are classified as “investments in unconsolidated companies” in the interim condensed consolidated balance sheets.

Recently Issued Accounting Guidance

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvement to Reportable Segment Disclosures.” The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit and loss, and contain other disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2023, which will be the Company's fiscal year 2024, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact this standard will have on our disclosures.

Table of Contents

Note 3 – Net Patient Revenues

The Company disaggregates revenue from contracts with customers by service type and by payor.

Revenue by Service Type

The Company’s net patient services can generally be classified into the following two categories: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services (in thousands).

	Three Months Ended March 31
	2024		2023
Net patient revenues:
Inpatient services	$	252,254	$	226,169
Homecare and hospice		33,569		31,838
Total net patient revenues	$	285,823	$	258,007

Table of Contents

For inpatient and hospice services, revenue is recognized on a daily basis as each day represents a separate contract and performance obligation. For homecare, revenue is recognized when services are provided based on the number of days of service rendered in the period of care or on a per-visit basis. Typically, patients and third-party payors are billed monthly after services are performed or the patient is discharged, and payments are due based on contract terms.

As our performance obligations relate to contracts with a duration of one year or less, the Company is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients are typically under no obligation to remain admitted in our facilities or under our care. As the period between the time of service and time of payment is typically one year or less, the Company did not adjust for the effects of a significant financing component.

Revenue by Payor

Certain groups of patients receive funds to pay the cost of their care from a common source. The following table sets forth sources of net patient revenues for the periods indicated:

	Three Months Ended March 31
Source	2024		2023
Medicare		34%		36%
Managed Care		10%		11%
Medicaid		28%		27%
Private Pay and Other		28%		26%
Total		100%		100%

Medicare covers skilled nursing services for beneficiaries who require nursing care and/or rehabilitation services following a hospitalization of at least three consecutive days. For each eligible day a Medicare beneficiary is in a skilled nursing facility, Medicare pays the facility a daily payment, subject to adjustment for certain factors such as a wage index in the geographic area. The payment covers all services provided by the skilled nursing facility for the beneficiary that day, including room and board, nursing, therapy and drugs, as well as an estimate of capital–related costs to deliver those services.

For homecare services, Medicare pays based on the acuity level of the patient and based on periods of care. A period of care is defined as a length of care up to 30 days with multiple continuous periods allowed. The services covered by the payment include all disciplines of care, in addition to medical supplies, within the scope of the home health benefit.

For hospice services, Medicare pays a daily rate to cover the hospice’s costs for providing services included in the patient care plan. Medicare makes daily payments based on 1 of 4 levels of hospice care. All hospice care and services offered to patients and their families must follow an individualized written plan of care that meets the patient’s needs.

Our hospice service revenue is subject to certain limitations on payments from Medicare. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded. If applicable, we record these cap adjustments as a reduction to revenue.

Medicaid is operated by individual states with the financial participation of the federal government. The states in which we operate currently use prospective cost–based reimbursement systems. Under cost–based reimbursement systems, the skilled nursing facility is reimbursed for the reasonable direct and indirect allowable costs it incurred in a base year in providing routine resident care services as defined by the program.

Private pay, managed care, and other payment sources include commercial insurance, individual patient funds, managed care plans and the Veterans Administration. Private paying patients, private insurance carriers and the Veterans Administration generally pay based on the healthcare center's charges or specifically negotiated contracts. For private pay patients in skilled nursing, assisted living and independent living facilities, the Company bills for room and board charges, with the remittance being due on receipt of the statement and generally by the 10th day of the month the services are performed.

Certain managed care payors for homecare services pay on a per-visit basis. This revenue is recorded on an accrual basis based upon the date of services at amounts equal to its established or estimated per-visit rates.

Table of Contents

State Relief Supplemental Funding

The Company received supplemental Medicaid payments from various states, including healthcare relief funding under the American Rescue Plan Act ("ARPA") and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses or various patient care related expenses. We have recorded $3,462,000 and $4,883,000 in net patient revenues for these supplemental Medicaid payments for the three months ended March 31, 2024 and 2023, respectively.

Contract Liabilities

Included in the Company’s interim condensed consolidated balance sheets are contract liabilities, which represent payments the Company receives in advance of services provided. As of March 31, 2024 and December 31, 2023, the Company has recorded $7,667,000 and $0, respectively, in contract liabilities related to receipts during the first quarter of 2024 from the Change Healthcare/Optum Payment Disruption ("CHOPD") Accelerated and Advance Payment program. These payments were issued to providers who experienced delays in the submission or processing of Medicare claims payments as a result of the Change Healthcare/Optum cyber incident, which began February 21, 2024. Recoupment of the accelerated payments began in the first quarter of 2024.

A summary of the activity related to contract liabilities follows (in thousands):

Balance at December 31, 2023	$	-
Payments received		9,881
Payments recouped		(2,214	)
Balance at March 31, 2024	$	7,667

Third Party Payors

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Noncompliance with such laws and regulations can be subject to regulatory actions including fines, penalties, and exclusion from the Medicare and Medicaid programs. We believe that we are following all applicable laws and regulations.

Medicare and Medicaid program revenues, as well as certain Managed Care program revenues, are subject to audit and retroactive adjustment by government representatives or their agents. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. We believe that any differences between the net revenues recorded, and final determination will not materially affect the consolidated financial statements. We have made provisions of approximately $19,988,000 and $18,369,000 as of March 31, 2024 and December 31, 2023, respectively, for various Medicare, Medicaid, and Managed Care claims reviews and current and prior year cost reports.

Note 4 – Other Revenues

Other revenues are outlined in the table below. Revenues from rental income include health care real estate properties owned by us and leased to third party operators. Revenues from management and accounting services include fees provided to manage and provide accounting services to other healthcare operators. Revenues from insurance services include premiums for workers’ compensation and professional liability insurance policies that our wholly owned insurance subsidiaries have written for certain healthcare operators to which we provide management or accounting services. "Other" revenues include miscellaneous health care related earnings (in thousands).

	Three Months Ended March 31
	2024		2023
Rental income	$	5,959	$	6,043
Management and accounting services fees		4,438		4,097
Insurance services		872		1,048
Other		84		368
Total other revenues	$	11,353	$	11,556

Rental Income

The Company leases real estate assets consisting of skilled nursing facilities and assisted living facilities to third party operators. Additionally, we sublease four Florida skilled nursing facilities included in our lease from National Health Investors (“NHI”) as noted in Note 7 – Long Term Leases.

Management Fees from National Health Corporation

We manage five skilled nursing facilities owned by National Health Corporation (“National”). For the three months ended March 31, 2024 and 2023, we recognized management fees and interest on management fees of $1,320,000 and $1,190,000, respectively, for these centers.

Table of Contents

Insurance Services

For workers’ compensation insurance services, the premium revenues reflected in the interim condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 were $582,000 and $736,000, respectively. Associated losses and expenses including those for self-insurance are included in the interim condensed consolidated statements of operations as "Salaries, wages and benefits."

For professional liability insurance services, the premium revenues reflected in the interim condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 were $290,000 and $312,000, respectively. Associated losses and expenses including those for self–insurance are included in the interim condensed consolidated statements of operations as "Other operating costs and expenses".

Note 5 – Non–Operating Income

Non–operating income is comprised of the following (in thousands):

	Three Months Ended March 31
	2024		2023
Dividends and net realized gains and losses on sales of securities	$	2,056	$	1,233
Interest income		2,538		1,555
Equity in earnings of unconsolidated investments		67		1,535
Gain on sale of unconsolidated company		1,024		-
Total non-operating income	$	5,685	$	4,323

Gain on sale of unconsolidated company

In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency located in Nashville, Tennessee. The total consideration paid to the company was $2,100,000, which resulted in a gain of $1,024,000.

Note 6 – Business Segments

The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals; and (2) homecare and hospice services. These reportable operating segments are consistent with information used by the Company’s Chief Executive Officer, as chief operating decision maker (“CODM”), to assess performance and allocate resources. The Company also reports an “all other” category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office.

The Company’s CODM evaluates performance and allocates capital resources to each segment based on an operating model that is designed to improve the quality of patient care and profitability of the Company while enhancing long-term shareholder value. The CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below.

Table of Contents

The following table sets forth the Company’s unaudited interim condensed consolidated statements of operations by business segment (in thousands):

	Three Months Ended March 31, 2024
	Inpatient Services		Homecare and Hospice		All Other			Total
Revenues:
Net patient revenues	$	252,254	$	33,569	$	-		$	285,823
Other revenues		15		-		11,338			11,353
Net operating revenues		252,269		33,569		11,338			297,176

Costs and expenses:
Salaries, wages, and benefits		150,890		21,009		11,239			183,138
Other operating		68,683		5,972		2,774			77,429
Rent		8,112		566		1,670			10,348
Depreciation and amortization		9,630		187		769			10,586
Interest		46		-		-			46
Total costs and expenses		237,361		27,734		16,452			281,547

Income/(loss) from operations		14,908		5,835		(5,114	)		15,629
Non-operating income		-		-		5,685			5,685
Unrealized gains on marketable equity securities		-		-		14,399			14,399

Income before income taxes	$	14,908	$	5,835	$	14,970		$	35,713

	Three Months Ended March 31, 2023
	Inpatient Services		Homecare and Hospice		All Other			Total
Revenues:
Net patient revenues	$	226,169	$	31,838	$	-		$	258,007
Other revenues		271		-		11,285			11,556
Net operating revenues		226,440		31,838		11,285			269,563

Costs and expenses:
Salaries, wages, and benefits		138,939		20,244		8,641			167,824
Other operating		62,264		5,499		3,726			71,489
Rent		8,168		558		1,366			10,092
Depreciation and amortization		9,117		185		746			10,048
Interest		98		-		-			98
Total costs and expenses		218,586		26,486		14,479			259,551

Income/(loss) from operations		7,854		5,352		(3,194	)		10,012
Non-operating income		-		-		4,323			4,323
Unrealized gains on marketable equity securities		-		-		1,386			1,386

Income before income taxes	$	7,854	$	5,352	$	2,515		$	15,721

Table of Contents

Note 7 – Long-Term Leases

Operating Leases

At March 31, 2024, we lease from NHI the real property of 28 skilled nursing facilities, five assisted living centers and three independent living centers under one lease agreement. As part of the lease agreement, we sublease four Florida skilled nursing facilities to a third-party operator. The lease includes base rent plus a percentage rent. The annual base rent is $32,625,000 in 2024, $32,225,000 in 2025, and $31,975,000 in 2026 with the lease term expiring in December 2026. The percentage rent is based on a quarterly calculation of revenue increases and is payable on a quarterly basis. Total facility rent expense to NHI was $9,472,000 and $9,295,000 for the three months ended March 31, 2024 and 2023, respectively.

Minimum Lease Payments

The following table summarizes the maturity of our operating lease liabilities as of March 31, 2024 (in thousands):

	Operating Leases
2025	$	34,351
2026		33,590
2027		24,933
2028		493
2029		207
Thereafter		21
Total minimum lease payments		93,595
Less: amounts representing interest		(7,858	)
Present value of future minimum lease payments		85,737
Less: current portion		(29,733	)
Noncurrent lease liabilities	$	56,004

Table of Contents

Note 8 – Earnings per Share

Basic net income per share is computed based on the weighted average number of common shares outstanding for each period presented. Diluted net income per share reflects the potential dilution that would have occurred if securities to issue common stock were exercised, converted, or resulted in the issuance of common stock that would have then shared in our earnings.

The following table summarizes the earnings and the weighted average number of common shares used in the calculation of basic and diluted earnings per share (in thousands, except for share and per share amounts):

	Three Months Ended March 31
	2024		2023
Basic:
Weighted average common shares outstanding		15,350,240		15,337,423
Net income attributable to National HealthCare Corporation	$	26,213	$	11,723
Earnings per common share, basic	$	1.71	$	0.76

Diluted:
Weighted average common shares outstanding		15,350,240		15,337,423
Effects of dilutive instruments		154,856		18,912
Weighted average common shares outstanding		15,505,096		15,356,335

Net income attributable to National HealthCare Corporation	$	26,213	$	11,723
Earnings per common share, diluted	$	1.69	$	0.76

For the three months ended March 31, 2024, 245,726 stock options have been excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect. For the three months ended March 31, 2023, 691,580 stock options have been excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect.

Note 9 – Investments in Marketable Securities

Our investments in marketable equity securities are carried at fair value with the changes in unrealized gains and losses recognized in our results of operations at each measurement date. Our investments in marketable debt securities are classified as available for sale securities and carried at fair value with the unrealized gains and losses recognized through accumulated other comprehensive income at each measurement date. Any credit-related decline in fair market values below the amortized cost of our available for sale debt securities are recorded in our results of operations through an allowance for credit losses. Realized gains and losses from securities sales are recognized in results of operations upon disposition of the securities using the specific identification method on a trade date basis. Refer to Note 10 for a description of the Company's methodology for determining the fair value of marketable securities.

Marketable securities consist of the following (in thousands):

	March 31, 2024				December 31, 2023
	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Investments available for sale:
Marketable equity securities	$	30,176	$	123,040	$	30,176	$	111,117
Corporate debt securities		494		484		2,497		2,441
U.S. Treasury securities		-		-		2,990		2,986
Restricted investments available for sale:
Marketable equity securities		24,495		29,616		24,134		26,779
Corporate debt securities		61,488		59,398		59,586		57,731
Asset-based securities		19,026		17,438		19,388		17,659
U.S. Treasury securities		47,323		43,004		46,771		42,863
State and municipal securities		4,079		3,992		4,106		4,047
	$	187,081	$	276,972	$	189,648		265,623

Table of Contents

Included in the marketable equity securities are the following (in thousands, except share amounts):

March 31, 2024

December 31, 2023

Cost

Fair

Value

Cost

Fair

Value

NHI Common Stock

1,630,642

24,734

102,453

1,630,642

24,734

91,071

The amortized cost and estimated fair value of debt securities classified as available for sale, by contractual maturity, are as follows (in thousands):

	March 31, 2024				December 31, 2023
	Cost		Fair Value		Cost		Fair Value
Maturities:
Within 1 year	$	21,299	$	20,785	$	19,664	$	19,328
1 to 5 years		77,738		73,370		81,517		77,118
6 to 10 years		32,012		28,925		33,515		30,802
Over 10 years		1,361		1,236		642		479
	$	132,410	$	124,316	$	135,338	$	127,727

Gross unrealized gains related to marketable equity securities are $98,459,000 and $84,514,000 as of March 31, 2024 and December 31, 2023, respectively. Gross unrealized losses related to marketable equity securities are $474,000 and $928,000 as of March 31, 2024 and December 31, 2023, respectively. For the three months ended March 31, 2024 and 2023, the Company recognized net unrealized gains of $14,399,000 and $1,386,000, respectively, for the changes in fair market value of the marketable equity securities in the interim condensed consolidated statements of operations.

Gross unrealized gains related to available for sale marketable debt securities are $179,000 and $326,000 as of March 31, 2024 and December 31, 2023, respectively. Gross unrealized losses related to available for sale marketable debt securities are $8,273,000 and $7,937,000 as of March 31, 2024 and December 31, 2023, respectively.

The Company’s unrealized losses in our available for sale marketable debt securities were determined to be non-credit related. The Company has not recognized any credit related impairments for the three months ended March 31, 2024 and 2023.

For the marketable securities in gross unrealized loss positions, (a) it is more likely than not that the Company will not be required to sell the investment securities before recovery of the unrealized losses, and (b) the Company expects that the contractual principal and interest will be received on the investment securities.

Proceeds from the sale of available for sale marketable securities during the three months ended March 31, 2024 and 2023 were $11,615,000 and $15,492,000, respectively. Investment gains of $344,000 and investment losses of $492,000 were realized on these sales during the three months ended March 31, 2024 and 2023, respectively.

Note 10 – Fair Value Measurements

The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This accounting standard establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs that may be used to measure fair value:

	Level 1 – The valuation is based on quoted prices in active markets for identical instruments.
	Level 2 – The valuation is based on observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model–based valuation techniques for which all significant assumptions are observable in the market.
	Level 3 – The valuation is based on unobservable inputs that are supported by minimal or no market activity and that are significant to the fair value of the instrument. Level 3 valuations are typically performed using pricing models, discounted cash flow methodologies, or similar techniques that incorporate management’s own estimates of assumptions that market participants would use in pricing the instrument, or valuations that require significant management judgment or estimation.

Table of Contents

A financial instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.

The following table summarizes fair value measurements by level at March 31, 2024 and December 31, 2023 for assets and liabilities measured at fair value on a recurring basis (in thousands):

	Fair Value Measurements Using
March 31, 2024	Fair Value		Quoted Prices in Active Markets For Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$	93,982	$	93,982	$	–	$	–
Restricted cash and cash equivalents		27,150		27,150		–		–
Marketable equity securities		152,656		152,656		–		–
Corporate debt securities		59,882		42,611		17,271		–
Asset–backed securities		17,438		–		16,961		477
U.S. Treasury securities		43,004		43,004		–		–
State and municipal securities		3,992		–		3,992		–
Total financial assets	$	398,104	$	359,403	$	38,224	$	477

	Fair Value Measurements Using
December 31, 2023	Fair Value		Quoted Prices in Active Markets For Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$	107,076	$	107,076	$	–	$	–
Restricted cash and cash equivalents		18,892		18,892		–		–
Marketable equity securities		137,896		137,896		–		–
Corporate debt securities		60,171		42,860		17,311		–
Asset–backed securities		17,659		–		17,210		449
U.S. Treasury securities		45,850		45,850		–		–
State and municipal securities		4,047		–		4,047		–
Total financial assets	$	391,591	$	352,574	$	38,568	$	449

Note 11 – Goodwill and Other Intangible Assets

At March 31, 2024, the Company reviewed the carrying value of goodwill for impairment indicators. As a result of the review, there were no impairment indicators regarding the Company’s goodwill that required a quantitative test to be performed. However, our accounting estimates could materially change from period to period due to changing market factors. We will continue to monitor future events, changes in circumstances, and the potential impact thereof. If actual results are not consistent with our assumptions and estimates, we may be exposed to future goodwill impairment losses.

At March 31, 2024, the following table represents the activity related to our goodwill by segment (in thousands):

	Inpatient Services		Homecare and Hospice		All Other		Total
January 1, 2024	$	3,741	$	164,554	$	–	$	168,295
Additions		–		–		–		–
March 31, 2024	$	3,741	$	164,554	$	–	$	168,295

We also have recorded indefinite-lived intangible assets that consist of trade names ($4,340,000) and certificates of need and licenses ($2,698,000).

Table of Contents

Note 12 - Stock Repurchase Program

During the three months ended March 31, 2024, the Company repurchased 101,131 shares of its common stock for a total cost of $9,900,000. During the three months ended March 31, 2023, the Company repurchased 44,349 shares of its common stock for a total cost of $2,482,000. The shares were funded from cash on hand and were cancelled and returned to the status of authorized but unissued.

Note 13 – Stock–Based Compensation

NHC recognizes stock–based compensation expense for all stock options granted over the requisite service period using the fair value at the date of grant using the Black–Scholes pricing model. Stock–based compensation totaled $793,000 and $639,000 for the three months ended March 31, 2024 and 2023, respectively. Stock–based compensation is included in “Salaries, wages and benefits” in the interim condensed consolidated statements of operations.

At March 31, 2024, the Company had $7,652,000 of unrecognized compensation cost related to unvested stock–based compensation awards. This unrecognized compensation cost will be amortized over an approximate three-year period.

Stock Options

The following table summarizes the significant assumptions used to value the options granted for the three months ended March 31, 2024 and for the year ended December 31, 2023.

	March 31, 2024		December 31, 2023
Risk–free interest rate		4.33%		4.52%
Expected volatility		24.1%		29.3%
Expected life, in years		2.9		2.9
Expected dividend yield		2.64%		4.41%

The following table summarizes our outstanding stock options for the three months ended March 31, 2024 and for the year ended December 31, 2023.

	Number of Shares			Weighted Average Exercise Price		Aggregate Intrinsic Value
Options outstanding at January 1, 2023		445,144		$	66.62	$	–
Options granted		299,278			54.44		–
Options exercised		(103,481	)		64.72		–
Options cancelled		(52,407	)		60.58		–
Options outstanding at December 31, 2023		588,534			61.30		–
Options granted		245,726			94.07		–
Options exercised		(137,874	)		60.95		–
Options outstanding at March 31, 2024		696,386		$	72.93	$	15,025,015

Options exercisable at March 31, 2024		174,105		$	68.48	$	4,531,876

Options Outstanding March 31, 2024	Exercise Prices			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years
377,405	53.94	-	69.19		58.92		3.5
318,981	71.64	-	94.10		89.51		4.0
696,386					72.93		3.7

Table of Contents

Note 14 – Income Taxes

The Company's income tax provision as a percentage of our income before income taxes was 26.5% and 28.2% for the three months ended March 31, 2024 and 2023, respectively.

Typically, these percentages vary from the U.S. federal statutory income tax rate of 21% primarily due to state income taxes, excess tax benefits from stock-based compensation, benefits resulting from the lapsing of statute of limitations of items in our tax contingency reserve, and non-deductible expenses. For the three months ended March 31, 2024 and 2023, the accrual of state income tax was the most significant reconciling item.

Our quarterly income tax provision, and our estimate of our annual effective income tax rate, is subject to variation due to several factors, including volatility based on the amount of pre-tax income or loss.

The Company is no longer subject to U.S. federal and state examinations by tax authorities for years before 2020 (with certain state exceptions).

Note 15 – Credit Facility

In May 2023, we entered into an unsecured $50,000,000 credit facility that has a 364-day maturity date. Loans bear interest at the one-month secured overnight financing rate (“SOFR”) plus 1.25%. If we maintain certain aggregate deposit levels within the financial institution, the credit facility shall bear interest at one-month SOFR plus 1.10%. The credit facility is available for general corporate purposes, including working capital and acquisitions. The credit facility agreement contains customary representations and financial covenants, including covenants that restrict, among other things, asset dispositions, additional indebtedness, investments, sale-leasebacks, and certain contingent liabilities. The credit facility contains customary events of default and remedies.

As of March 31, 2024, the Company had no outstanding balance on the credit facility. We do not expect to renew this credit facility upon its maturity date.

Note 16 – Contingencies and Commitments

Accrued Risk Reserves

We have wholly-owned limited purpose insurance companies that insure risks related to workers’ compensation and professional liability insurance claims both for our owned and leased entities and certain of the entities to which we provide management or accounting services. The liability we have recognized for reported claims and estimates for incurred but unreported claims totals $108,237,000 and $103,259,000 at March 31, 2024 and December 31, 2023, respectively. The liability is included in accrued risk reserves in the interim condensed consolidated balance sheets and is subject to adjustment for actual claims incurred. It is possible that these claims plus unasserted claims could exceed our insurance coverages and our reserves, which could have a material adverse effect on our consolidated financial position, results of operations and cash flows.

As a result of the terms of our insurance policies and our use of wholly owned limited purpose insurance companies, we have retained significant insurance risk with respect to workers’ compensation and general and professional liability. We consider the professional services of independent actuaries to assist us in estimating our exposures for claims obligations (for both asserted and unasserted claims) related to deductibles and exposures in excess of coverage limits, and we maintain reserves for these obligations. Such estimates are based on many variables including historical and statistical information and other factors.

Workers’ Compensation

For workers’ compensation, we utilize a wholly–owned Tennessee domiciled property/casualty insurance company to write coverage for NHC affiliates and for third–party customers. Policies are written for a duration of twelve months and cover only risks related to workers’ compensation losses. All customers are companies which operate in the senior care industry. Business is written on a direct basis.

General and Professional Liability Insurance and Lawsuits

The senior care industry has experienced significant increases in both the number of personal injury/wrongful death claims and in the severity of awards based upon alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. Additional insurance is purchased through third party providers that serve to supplement the coverage provided through our wholly owned captive insurance company.

There is certain additional litigation incidental to our business, none of which, based upon information available to date, would be material to our financial position, results of operations, or cash flows. In addition, the long–term care industry is continuously subject to scrutiny by governmental regulators, which could result in litigation or claims related to regulatory compliance matters.

Table of Contents

Qui Tam Litigation

United States of America, ex rel. Jennifer Cook and Sally Gaither v. Integrated Behavioral Health, Inc., NHC HealthCare/Moulton, LLC, et al., Case No. 2:20-CV-00877-AMM (N.D. Ala.) This is a qui tam case originally filed under seal on June 22, 2020. The United States declined intervention on March 1, 2021. Thereafter, the Plaintiffs filed an amended Complaint against Dr. Sanja Malhotra, Integrated Behavioral Health, Inc. and other entities that Dr. Malhotra was alleged to own or in which he allegedly had a financial interest. The Complaint also named multiple skilled nursing facilities as Defendants, including NHC Healthcare/Moulton, LLC, an affiliate of National HealthCare Corporation. The Complaint alleged that nurse practitioners affiliated with Dr. Malhotra provided free services to the facilities in exchange for referrals to entities owned by or in which Dr. Malhotra had a financial interest in violation of the False Claims Act and Anti-Kickback Statute. NHC Healthcare/Moulton, LLC denied the allegations and filed a motion to dismiss on November 4, 2021. On January 28, 2022, the district court stayed this matter and administratively terminated the motion to dismiss pending the U.S. Supreme Court's review of a petition for certiorari filed in an unrelated matter but involving one of the legal arguments raised in the motion to dismiss. Thereafter, the U.S. Supreme Court denied the petition for certiorari in the unrelated matter. As a result, NHC Healthcare/Moulton, LLC renewed its motion to dismiss. The District Court granted NHC Healthcare/Moulton’s Motion to Dismiss, along with other pending Motions to Dismiss, and entered an Order of Dismissal on March 23, 2023 and an Amended Order of Dismissal on April 4, 2023, which dismissed the case in its entirety with prejudice with respect to the claims asserted by the Plaintiffs. The Plaintiffs filed a Notice of Appeal on April 20, 2023 to appeal the dismissal to the United States Court of Appeals for the Eleventh Circuit. On December 21, 2023, the Eleventh Circuit entered an Order affirming the District Court’s dismissal of the claims. The time period for the Plaintiffs to file a Petition for a Writ of Certiorari with the United States Supreme Court has expired making the Order affirming dismissal issued by the Eleventh Circuit final.

Governmental Regulations

Laws and regulations governing Medicare, Medicaid and other federal healthcare programs are complex and subject to interpretation. Management believes that it is following all applicable laws and regulations in all material respects. However, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusions from the Medicare, Medicaid and other federal healthcare programs.

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward–Looking Statements

References throughout this document to the Company include National HealthCare Corporation and its wholly owned subsidiaries. In accordance with the Securities and Exchange Commissions “Plain English” guidelines, this Quarterly Report on Form 10–Q has been written in the first person. In this document, the words “we”, “our”, “ours” and “us” refer only to National HealthCare Corporation and its wholly–owned subsidiaries and not any other person.

This Quarterly Report on Form 10–Q and other information we provide from time to time, contains certain “forward–looking” statements as that term is defined by the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations or cash flows, continued performance improvements, ability to service and refinance our debt obligations, ability to finance growth opportunities, ability to control our patient care liability costs, ability to respond to changes in government regulations, ability to execute our three–year strategic plan, and similar statements including, without limitations, those containing words such as “believes”, “anticipates”, “expects”, “intends”, “estimates”, “plans”, and other similar expressions are forward–looking statements.

Table of Contents

Forward–looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward–looking statements as a result of, but not limited to, the following factors:

●	national and local economic conditions, including their effect on the availability and cost of labor, utilities and materials;

●	the effect of government regulations and changes in regulations governing the healthcare industry, including our compliance with such regulations;

●	changes in Medicare and Medicaid payment levels and methodologies and the application of such methodologies by the government and its fiscal intermediaries;

●	liabilities and other claims asserted against us, including patient care liabilities, as well as the resolution of current litigation (see Note 16: Contingencies and Commitments);

●	the ability to attract and retain qualified personnel;

●	the availability and terms of capital to fund acquisitions and capital improvements;

●	the competitive environment in which we operate;

●	our need to make investments continually in our processes and information systems to protect the privacy of patients, partners and other persons and reduce the risk of successful cybersecurity attacks;

●	damage to our reputation, regulatory penalties, legal claims and liability under state and federal laws that we could suffer upon any cybersecurity or privacy breaches;

●	the ability to maintain and increase census levels; and

●	demographic changes.

See the notes to the quarterly financial statements, and “Item 1. Business” in our 2023 Annual Report on Form 10–K for a discussion of various governmental regulations and other operating factors relating to the healthcare industry and the risk factors inherent in them. This may be found on our web site at www.nhccare.com. You should carefully consider these risks before making any investment in the Company. These risks and uncertainties are not the only ones facing us. There may be additional risks that we do not presently know of or that we currently deem immaterial. If any of the risks occur, our business, financial condition or results of operations could be materially adversely affected. In that case, the trading price of our shares of stock could decline, and you may lose all or part of your investment. Given these risks and uncertainties, we can give no assurances that these forward–looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them.

Overview

National HealthCare Corporation (“NHC” or the “Company”) is a leading provider of senior health care services. As of March 31, 2024, we operate or manage, through certain affiliates, 65 skilled nursing facilities with a total of 8,421 licensed beds, 24 assisted living facilities with 1,365 units, five independent living facilities, three behavioral health hospitals, 35 homecare agencies, and 30 hospice agencies. We operate specialized care units within certain of our healthcare centers such as Alzheimer's disease care units and sub-acute nursing units. In addition, we provide insurance services, management and accounting services, and we lease properties to operators of skilled nursing and assisted living facilities. We operate in 8 states and are located primarily in the southeastern United States.

Centers for Medicare and Medicaid Services Minimum Staffing Standards

On April 22, 2024, the Centers for Medicare and Medicaid Services (“CMS”) issued the Minimum Staffing Standards for Long-Term Care (“LTC”) Facilities and Medicaid Institutional Payment Transparency Reporting final rule. Included in this final rule are new comprehensive minimum nurse staffing requirements, which aim to significantly reduce the risk of residents receiving unsafe and low-quality care within LTC facilities. CMS is finalizing a total nurse staffing standard of 3.48 hours per resident day (“HPRD”), which must include at least 0.55 HPRD of direct registered nurse (“RN”) care and 2.45 HPRD of direct nurse aide care. Facilities may use any combination of nurse staff (RN, licensed practical nurse and licensed vocational nurse, or nurse aide) to account for the additional 0.48 HPRD needed to comply with the total nurse staffing standard.

Table of Contents

CMS is also finalizing enhanced facility assessment requirements and a requirement to have an RN onsite 24 hours a day, seven days a week (“24/7”), to provide skilled nursing care. The 24/7 RN onsite can be the Director of Nursing; however, they must be available to provide direct resident care.

This final rule provides a staggered implementation timeframe of the minimum nurse staffing standards and a 24/7 RN requirement based on geographic location, as well as possible exemptions for qualifying facilities for some parts of these requirements based on workforce unavailability and other factors.

Summary of Goals and Areas of Focus

Occupancy

A primary area of management focus continues to be the rates of occupancy within our skilled nursing facilities. The overall census in owned and leased skilled nursing facilities for the three months ending March 31, 2024 was 88.5% compared to 87.4% for the same period a year ago.

Due to America’s healthcare labor shortage, the challenge of maintaining desirable patient census levels has been amplified. Management has undertaken a number of steps in order to best position our current and future health care facilities. This includes working internally to examine and improve systems to be most responsive to referral sources and payors, as well as find creative initiatives to retain and attract qualified healthcare professionals. Additionally, NHC is in various stages of partnerships with hospital systems, payors, and other post–acute alliances to better position ourselves so we are an active participant in the delivery of post-acute healthcare services.

Table of Contents

Quality of Patient Care

CMS introduced the Five-Star Quality Rating System to help consumers, their families and caregivers compare skilled nursing facilities more easily. The Five-Star Quality Rating System gives each skilled nursing operation a rating ranging between one and five stars in various categories (five stars being the best). The Company has always strived for patient-centered care and quality outcomes as precursors to outstanding financial performance.

The tables below summarize NHC's overall performance in these Five-Star ratings versus the skilled nursing industry as of March 31, 2024:

	NHC Ratings		Industry Ratings
Total number of skilled nursing facilities, end of period		65
Number of 4 and 5-star rated skilled nursing facilities		40
Percentage of 4 and 5-star rated skilled nursing facilities		62%		36%
Average rating for all skilled nursing facilities, end of period		3.6		2.9

Development and Growth

We are undertaking to expand our senior care operations while protecting our existing operations and markets. The following table lists our recent development activities.

Type of

Operation

Description

Size

Location

Placed in Service

Hospice

New Agency

1 agency

Cedar Bluff, VA

March 2023

Skilled Nursing

Acquisition

66 beds

Nashville, TN

May 2023

Homecare

New Agency

1 agency

Tallahassee, FL

May 2023

Assisted Living Facility

New Operations

135 units

Vero Beach, FL

July 2023

Assisted Living Facility

New Operations

95 units

Merritt Island, FL

July 2023

Assisted Living Facility

New Operations

100 units

Stuart, FL

July 2023

Hospice

New Agency

1 agency

Morristown, TN

April 2024

Accrued Risk Reserves

Our accrued professional liability and workers’ compensation reserves totaled $108,237,000 at March 31, 2024 and are a primary area of management focus. We have set aside restricted cash and cash equivalents and marketable securities to fund our estimated professional liability and workers’ compensation liabilities.

As to exposure for professional liability claims, we have developed performance certification criteria to measure and bring focus to the patient care issues most likely to produce professional liability exposure, including in–house acquired pressure ulcers, significant weight loss and numbers of falls. These programs for certification, which we regularly modify and improve, have produced measurable improvements in reducing these incidents. Our experience is that achieving goals in these patient care areas improves both patient and employee satisfaction.

Government Reimbursement Programs

Medicare – Skilled Nursing Facilities

In July 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates and policy changes for skilled nursing facilities, which began on October 1, 2023. The fiscal year 2024 rule equates to a net increase of 4.0%, or approximately $1.4 billion, in Medicare Part A payments to SNFs in fiscal year 2024 compared to 2023 levels. The rule includes a 3.0% market basket rate increase, a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment, as well as a negative 2.3%, or approximately $789 million, decrease in 2024 SNF Payment Prospective Systems rates as a result of the second phase of the Patient Driven Payment Model parity adjustment recalibration.

In March 2024, CMS released its proposed rule outlining fiscal year 2025 Medicare payment rates and policy changes for skilled nursing facilities, which will begin on October 1, 2024. The fiscal year 2025 proposal equates to a net 4.1% increase in Medicare Part A payments to SNFs in fiscal year 2025 compared to 2024 levels. The rule includes a market basket increase of 2.8%, an increase of 1.7% to the market basket forecast error adjustment, and a negative 0.4% productivity adjustment. These figures do not incorporate the SNF Value Based Purchasing (“VBP”) reduction for certain SNFs subject to the net reduction in payments under the SNF VBP; those adjustments are estimated to total $196.5 million in fiscal year 2025.

For the first three months of 2024, our average Medicare per diem rate for skilled nursing facilities increased 4.7% as compared to the same period in 2023.

Table of Contents

Medicaid – Skilled Nursing Facilities

Effective July 1, 2023 and for the fiscal year 2024, the state of Tennessee implemented specific individual nursing facility increases. We estimate the resulting increase in revenue for the 2024 fiscal year will be approximately $15,000,000 annually, or $3,750,000 per quarter.

Effective October 1, 2023 and for the fiscal year 2024, the state of South Carolina implemented specific individual nursing facility increases. We estimate the resulting increase in revenue for the 2024 fiscal year will be approximately $9,000,000 annually, or $2,250,000 per quarter.

Effective July 1, 2023 and for the fiscal year 2024, the state of Missouri implemented specific individual nursing facility increases. We estimate the resulting increase in revenue for the 2024 fiscal year will be approximately $5,000,000 annually, or $1,250,000 per quarter.

We have also received from many of the states in which we operate a supplemental Medicaid payment to help mitigate the inflationary labor and medical supplies costs resulting from the pandemic. We have recorded $3,462,000 and $4,883,000 in net patient revenues for these supplemental Medicaid payments for the three months ended March 31, 2024 and 2023, respectively.

For the first three months of 2024, our average Medicaid per diem increased 12.0% compared to the same period in 2023.

State Medicaid plans subject to budget constraints are of particular concern to us. Changes in federal funding coupled with state budget problems and Medicaid expansion under the Affordable Care Act have produced an uncertain environment. Some states will not keep pace with post-acute healthcare inflation. States are currently under pressure to pursue other alternatives to skilled nursing care such as community and home–based services. Medicaid programs are funded jointly by the federal government and the states and are administered by states under approved plans. Most state Medicaid payments are made under a prospective payment system or under programs which negotiate payment levels with individual providers. Some states use, or have applied to use, waivers granted by CMS to implement expansion, impose different eligibility or enrollment restrictions, or otherwise implement programs that vary from federal standards.

Medicare – Homecare Programs

In November 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates. CMS projects payments to home health agencies in fiscal year 2024 will increase in aggregate by 0.8%, or $140 million. The increase is the result of a 3.3% market basket update, reduced by a 0.3% productivity adjustment. The increase is offset by a behavioral adjustment that will cut payments by a net 2.6%. The behavioral adjustment was designed to achieve budget-neutral implementation of the PDPM. Finally, CMS also adjusted the fixed-dollar loss ratio for outlier payments, which will increase payments by 0.4%.

Medicare – Hospice

In July 2023, CMS released its final rule outlining fiscal year 2024 Medicare payment rates. CMS issued a rate increase of 3.1%, or $780 million, effective October 1, 2023. This increase is the result of a 3.3% market basket increase reduced by a 0.2% productivity adjustment. The FY2024 hospice payment update also includes an update to the statutory aggregate cap amount, which limits the overall payments per patient that are made annually. The cap amount for FY2024 is $33,494.

In March 2024, CMS released its proposed rule outlining fiscal year 2025 Medicare payment rates. CMS issued a rate increase of 2.6%, or $705 million, effective October 1, 2024. This increase is the result of a 3.0% market basket increase reduced by a 0.4% productivity adjustment. The FY2025 hospice payment update also includes an update to the statutory aggregate cap amount, which limits the overall payments per patient that are made annually. The proposed cap amount for FY2025 is $34,365.

Table of Contents

Segment Reporting

The Company’s CODM evaluates performance and allocates capital resources to each segment based on an operating model that is designed to improve the quality of patient care and profitability of the Company while enhancing long-term shareholder value. The CODM does not review assets by segment in his resource allocation and therefore, assets by segment are not disclosed below.

The following table sets forth the Company’s unaudited interim condensed consolidated statements of operations by business segment (in thousands):

	Three Months Ended March 31, 2024
	Inpatient Services		Homecare and Hospice		All Other			Total
Revenues:
Net patient revenues	$	252,254	$	33,569	$	-		$	285,823
Other revenues		15		-		11,338			11,353
Net operating revenues		252,269		33,569		11,338			297,176

Costs and expenses:
Salaries, wages, and benefits		150,890		21,009		11,239			183,138
Other operating		68,683		5,972		2,774			77,429
Rent		8,112		566		1,670			10,348
Depreciation and amortization		9,630		187		769			10,586
Interest		46		-		-			46
Total costs and expenses		237,361		27,734		16,452			281,547

Income/(loss) from operations		14,908		5,835		(5,114	)		15,629
Non-operating income		-		-		5,685			5,685
Unrealized gains on marketable equity securities		-		-		14,399			14,399

Income before income taxes	$	14,908	$	5,835	$	14,970		$	35,713

	Three Months Ended March 31, 2023
	Inpatient Services		Homecare and Hospice		All Other			Total
Revenues:
Net patient revenues	$	226,169	$	31,838	$	-		$	258,007
Other revenues		271		-		11,285			11,556
Net operating revenues		226,440		31,838		11,285			269,563

Costs and expenses:
Salaries, wages, and benefits		138,939		20,244		8,641			167,824
Other operating		62,264		5,499		3,726			71,489
Rent		8,168		558		1,366			10,092
Depreciation and amortization		9,117		185		746			10,048
Interest		98		-		-			98
Total costs and expenses		218,586		26,486		14,479			259,551

Income/(loss) from operations		7,854		5,352		(3,194	)		10,012
Non-operating income		-		-		4,323			4,323
Unrealized gains on marketable equity securities		-		-		1,386			1,386

Income before income taxes	$	7,854	$	5,352	$	2,515		$	15,721

Table of Contents

Non-GAAP Financial Presentation

The Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company’s operations and measure the Company’s performance more consistently across periods. Therefore, the Company believes this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

Specifically, the Company believes the presentation of non-GAAP financial information that excludes the unrealized gains or losses on our marketable equity securities, operating results for start-up healthcare operations not at full capacity, gains on sale of unconsolidated companies, and share-based compensation expense is helpful in allowing investors to assess the Company’s operations more accurately.

The operating results for the newly constructed healthcare facilities not at full capacity for the three months ended March 31, 2024 include facilities that began operations from 2022 to 2024, which is two behavioral health hospitals, two homecare agencies, and two hospice agencies. For the three months ended March 31, 2023, included are facilities that began operations from 2021 to 2023, which is two behavioral health hospitals, one homecare agency, and two hospice agencies.

The tables below provide reconciliations of GAAP to non-GAAP items (dollars in thousands, except per share data):

	Three Months Ended March 31
	2024			2023

Net income attributable to National Healthcare Corporation	$	26,213		$	11,723
Non-GAAP adjustments
Unrealized gains on marketable equity securities		(14,399	)		(1,386	)
Operating results for newly opened facilities or agencies not at full capacity		(457	)		1,217
Gain on sale of unconsolidated company		(1,025	)		-
Share-based compensation expense		793			639
Income tax provision/(benefit) on non-GAAP adjustments		3,923			(122	)
Non-GAAP Net income	$	15,048		$	12,071


GAAP diluted earnings per share	$	1.69		$	0.76
Non-GAAP adjustments
Unrealized gains on marketable equity securities		(0.69	)		(0.06	)
Operating results for newly opened facilities or agencies not at full capacity		(0.02	)		0.06
Gain on sale of unconsolidated company		(0.05	)		-
Share-based compensation expense		0.04			0.03
Non-GAAP diluted earnings per share	$	0.97		$	0.79

Table of Contents

Results of Operations

The following table and discussion set forth items from the interim condensed consolidated statements of operations as a percentage of net operating revenues for the three months ended March 31, 2024 and 2023.

Percentage of Net Operating Revenues

	Three Months Ended March 31
	2024			2023
Net operating revenues		100.0	%		100.0	%
Costs and expenses:
Salaries, wages, and benefits		61.6			62.3
Other operating		26.0			26.5
Facility rent		3.5			3.7
Depreciation and amortization		3.5			3.7
Interest		0.1			0.1
Total costs and expenses		94.7			96.3
Income from operations		5.3			3.7
Non–operating income		1.9			1.6
Unrealized gains on marketable equity securities		4.8			0.5
Income before income taxes		12.0			5.8
Income tax provision		(3.2	)		(1.6	)
Net income		8.8			4.2
Net (income)/loss attributable to noncontrolling interest		(0.0	)		0.1
Net income attributable to stockholders of NHC		8.8	%		4.3	%

Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023

Results for the quarter ended March 31, 2024 compared to the first quarter of 2023 include a 10.2% increase in net operating revenues. For the quarter ended March 31, 2024, GAAP net income attributable to NHC was $26,213,000 compared to $11,723,000 for the same period in 2023. Excluding the unrealized gains in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended March 31, 2024 was $15,048,000 compared to $12,071,000 for the same period in 2023. The increase in adjusted net income for the first quarter of 2024 compared to the first quarter of 2023 was primarily due the continued occupancy increase in our skilled nursing and assisted living facilities, skilled nursing per diem increases from some of our governmental payors, and the continued reduction of nurse agency staffing expense within our operations.

Net operating revenues

Net patient revenues increased $27,816,000, or 10.8%, compared to the same period last year.

The total census at owned and leased skilled nursing facilities for the quarter averaged 88.5%, compared to an average of 87.4% for the same quarter a year ago. Overall, the composite skilled nursing facility per diem increased 8.8% compared to the same quarter a year ago. Our Medicare per diem rates increased 4.7% and managed care per diem rates increased 5.8% compared to the same quarter a year ago. Medicaid and private pay per diem rates increased 12.0% and 10.5%, respectively, compared to the same quarter a year ago. For the three months ended March 31, 2024 and 2023, respectively, $3,462,000 and $4,883,000 have been included in our net patient revenues for supplemental Medicaid payments that are in addition to our Medicaid skilled nursing per diems.

New operations, which include one skilled nursing facility acquired May 1, 2023, three assisted living facilities that we began operating on July 1, 2023, two behavioral health hospitals, two hospice agencies and two homecare agencies, have attributed to an increase of $7,727,000 in net patient revenues for the quarter ended March 31, 2024 compared to the same quarter in the prior year.

On March 1, 2024, the Company exited a lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in net patient revenues decreasing $1,972,000 for the quarter ended March 31, 2024 compared to the same quarter in the prior year.

Other revenues decreased $203,000, or 1.8%, compared to the same quarter last year, as further detailed in Note 4 to our interim condensed consolidated financial statements.

Table of Contents

Total costs and expenses

Total costs and expenses for the three months ended March 31, 2024 compared to the same period of 2023 increased $21,996,000, or 8.5% to $281,547,000 from $259,551,000.

Salaries, wages, and benefits as a percentage of net operating revenues was 61.6% compared to 62.3% for the three months ended March 31, 2024 and 2023, respectively. We continue to face workforce and labor shortages within all of our operations, which increases wage pressure in regards to retaining and attracting qualified healthcare partners (employees). We continue to work diligently to find solutions to reduce and eliminate the agency nurse staffing within our healthcare operations. Our agency staffing expense decreased approximately 51% for the three months ended March 31, 2024 compared to the same period of 2023.

New operations, which include one skilled nursing facility acquired May 1, 2023, three assisted living facilities that we began operating on July 1, 2023, two behavioral health hospitals, two hospice agencies and two homecare agencies, have attributed to an increase of $3,591,000 in salaries, wages, and benefits for the quarter ended March 31, 2024 compared to the same quarter in the prior year.

On March 1, 2024, the Company exited the lease and transferred the operations of two skilled nursing facilities (included assisted living units) and one memory care facility located in Missouri. The exiting of these operations resulted in salaries, wages, and benefits decreasing $1,799,000 for the quarter ended March 31, 2024 compared to the same quarter in the prior year.

Other operating expenses as a percentage of net operating revenues was 26.1% and 26.5% for the three months ended March 31, 2024 and 2023, respectively. New operations, which include one skilled nursing facility acquired May 1, 2023, three assisted living facilities that we began operating on July 1, 2023, two behavioral health hospitals, two hospice agencies and two homecare agencies, have attributed to an increase of $2,176,000 in other operating expenses for the quarter ended March 31, 2024 compared to the same quarter in the prior year. We continue to face inflationary pressures in certain categories within other operating expenses as well, such as food/dietary supplies and drugs/pharmaceutical supplies.

Other income

Non–operating income increased by $1,362,000 compared to the same period last year, as further detailed in Note 5 to our interim condensed consolidated financial statements. In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency located in Nashville, Tennessee. The total consideration paid to the company was $2,100,000, which resulted in a gain of $1,025,000.

Income taxes

The income tax provision for the three months ended March 31, 2024 is $9,462,000 (an effective income tax rate of 26.5%).

Noncontrolling interest

The noncontrolling interest in subsidiaries is presented within total equity of the Company’s consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its consolidated statements of operations. The Company’s earnings per share is calculated based on net income attributable to NHC’s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022

Results for the quarter ended March 31, 2023 compared to the first quarter of 2022 include a 3.4% decrease in net operating revenues and grant income. The net operating revenues and grant income decrease was primarily driven by the reduction in government stimulus income of $10,620,000 during the first quarter of 2023 compared to the same period a year ago, as well as us exiting seven skilled nursing facilities in Massachusetts and New Hampshire during the third quarter of 2022. Excluding the government stimulus income and the seven skilled nursing facilities in Massachusetts and New Hampshire, same-facility net operating revenues increased 7.1% during the first quarter of 2023 compared to the same period a year ago.

For the quarter ended March 31, 2023, GAAP net income attributable to NHC was $11,723,000 compared to net income of $15,318,000 for the same period in 2022. Excluding the unrealized gains in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended March 31, 2023 was $12,071,000 compared to $14,081,000 for the same period in 2022. The decrease in adjusted net income for the first quarter of 2023 compared to the first quarter of 2022 was primarily due to the $10,620,000 less in government stimulus income recorded during the current quarter.

Table of Contents

Net operating revenues and grant income

Net patient revenues increased $1,670,000, or 0.7%, compared to the same period last year.

The total census at owned and leased skilled nursing facilities for the quarter averaged 87.4%, compared to an average of 82.7% for the same quarter a year ago. Overall, the composite skilled nursing facility per diem increased 3.3% compared to the same quarter a year ago. Our Medicare per diem rates increased 2.1% and managed care per diem rates increased 2.7% compared to the same quarter a year ago. Medicaid and private pay per diem rates increased 3.6% and 3.1%, respectively, compared to the same quarter a year ago. For the three months ended March 31, 2023 and 2022, respectively, $4,883,000 and $5,538,000 have been included in our net patient revenues for supplemental COVID-19 Medicaid payments.

In September 2022, the Company transferred the operations of seven skilled nursing facilities located in Massachusetts and New Hampshire resulting in net patient revenues decreasing $16,603,000 for the three months ended March 31, 2023 compared to the same quarter last year.

Other revenues decreased $470,000, or 3.9%, compared to the same quarter last year, as further detailed in Note 4 to our interim condensed consolidated financial statements.

During the three months ended March 31, 2023 and 2022, respectively, we recorded $0 and $10,620,000 in government stimulus income related to funds received from the CARES Act Provider Relief Fund.

Table of Contents

Total costs and expenses

Total costs and expenses for the three months ended March 31, 2023 compared to the same period of 2022 decreased $5,215,000, or 2.0% to $259,551,000 from $264,766,000.

Salaries, wages, and benefits as a percentage of net operating revenues and grant income was 62.3% compared to 61.2% for the three months ended March 31, 2023 and 2022, respectively. We continue to face workforce and labor shortages within all of our operations, which increases wage pressure in regards to retaining and attracting qualified healthcare partners (employees). The labor and workforce shortages have resulted in us contracting with agency nurse staffing companies. The agency nurse staffing companies charge inflated hourly rates; therefore, we are working diligently to find solutions to reduce and eliminate the agency nurse staffing within our healthcare operations. For the quarter ended March 31, 2023, our agency nurse staffing expense decreased $4,941,000, or approximately 34%, compared to the same period a year ago.

In September 2022, the Company transferred the operations of seven skilled nursing facilities located in Massachusetts and New Hampshire resulting in salaries, wages, and benefits decreasing $11,884,000 for the three months ended March 31, 2023 compared to the same quarter last year.

Other operating expenses as a percentage of net operating revenues and grant income was 26.5% and 26.6% for the three months ended March 31, 2023 and 2022, respectively. The transfer of the operations of the seven skilled nursing facilities located in Massachusetts and New Hampshire, as noted above, resulted in other operating expenses decreasing $5,206,000 for the three months ended March 31, 2023 compared to the same quarter last year. We continue to face inflationary pressures in certain categories within other operating expenses as well, such as food/dietary supplies and drugs/pharmaceutical supplies.

Other income

Non–operating income increased by $1,124,000 compared to the same period last year, as further detailed in Note 5 to our interim condensed consolidated financial statements.

Income taxes

The income tax provision for the three months ended March 31, 2023 is $4,436,000 (an effective income tax rate of 28.2%).

Noncontrolling interest

Liquidity, Capital Resources, and Financial Condition

Our primary sources of cash include revenues from the operations of our healthcare and senior living facilities, management and accounting services, rental income, and investment income. Our primary uses of cash include salaries, wages and other operating costs of our healthcare and senior living facilities, the cost of additions to and acquisitions of real property, facility rent expenses, and dividend distributions. These sources and uses of cash are reflected in our interim condensed consolidated statements of cash flows and are discussed in further detail below.

The following is a summary of our sources and uses of cash flows (dollars in thousands):

	Three Months Ended March 31						Three Month Change
	2024			2023			$			%
Cash, cash equivalents, restricted cash, and restricted cash equivalents, at beginning of period	$	125,968		$	74,865		$	51,103			68.3	%

Cash provided by operating activities		9,646			13,857			(4,211	)		(30.4	)

Cash used in investing activities		(2,415	)		(1,427	)		(988	)		(69.2	)

Cash used in financing activities		(12,067	)		(12,619	)		552			4.4

Cash, cash equivalents, restricted cash, and restricted cash equivalents, at end of period	$	121,132		$	74,676		$	46,456			62.2	%

Table of Contents

Operating Activities

Net cash provided by operating activities for the three months ended March 31, 2024 was $9,646,000 as compared to 13,857,000 in the same period last year. Cash provided by operating activities consisted of net income of $26,251,000 and decreases to operating cash flows related to adjustments for non–cash items of $1,627,000. There was cash used for working capital needs in the amount of $14,634,000 for the three months ended March 31, 2024 compared to $6,017,000 for the same period a year ago.

On February 21, 2024, Change Healthcare was the target of a ransomware attack. The Company uses Change Healthcare as an intermediary to process and pay our governmental and insurance company healthcare claims. With Change Healthcare’s systems being down during the first quarter of 2024, we had to manually bill the majority of our skilled nursing claims for the months of February and March 2024. Although we manually billed our skilled nursing healthcare claims in February and March 2024, we were not paid as we typically would in the ordinary course of business. At March 31, 2024, our patient accounts receivable balances increased approximately $15 million from our December 31, 2023 accounts receivable balances. We believe this increase in accounts receivable is temporary and over the next several months we expect our accounts receivable balances and operating cash flow to be back to normal levels.

Included in the adjustments for non-cash items are depreciation expense, equity in earnings of unconsolidated investments, unrealized gains on our marketable equity securities, gain on sale of an unconsolidated company, deferred taxes, and stock compensation.

Investing Activities

Net cash used in investing activities totaled $2,415,000 for the three months ended March 31, 2024, compared to $1,427,000 for the three months ended March 31, 2023. Cash used for property and equipment additions was $5,955,000 and $6,640,000 for the three months ended March 31, 2024, and 2023, respectively. Proceeds from the sale of marketable securities, net of purchases, resulted in cash provided by investing activity of $2,912,000 and $5,211,000 for the three months ended March 31, 2024 and 2023, respectively. In January 2024, the Company sold its 50% joint venture ownership interest in a homecare agency resulting in proceeds from the sale of $2,100,000.

Financing Activities

Net cash used in financing activities totaled $12,067,000 for the three months ended March 31, 2024 compared to $12,619,000 for the three months ended March 31, 2023. We made principal payments under our finance lease obligations in the amount of $860,000 and $1,218,000 for the three months ended March 31, 2024 and 2023, respectively. Cash used for dividend payments to common stockholders totaled $9,051,000 in the current year period compared to $8,748,000 for the same period a year ago. Cash provided by the issuance of common stock totaled $8,412,000 for the quarter ended March 31, 2024. We repurchased common shares outstanding in the amount of $9,900,000 and $2,482,000 for the three months ended March 31, 2024 and 2023, respectively.

Short–term liquidity

We expect to meet our short-term liquidity requirements primarily from our cash flows from operating activities. In addition to cash flows from operations, our current cash on hand of $93,982,000 and our marketable equity and debt securities of $123,524,000 are expected to be adequate to meet our contractual obligations, operating liquidity, and our growth and development plans in the next twelve months. We also have substantial value in our unencumbered real estate assets, which could potentially be used as collateral in future borrowing opportunities.

Long–term liquidity

We expect to meet our long-term liquidity requirements primarily from our cash flows from operating activities, our current cash on hand of $93,982,000 and our marketable equity and debt securities of $123,524,000. We also have substantial value in our unencumbered real estate assets, which could potentially be used as collateral in future borrowing opportunities.

Our ability to meet our long–term contractual obligations, and to finance our operating requirements and growth plans will depend upon our future performance. Our future performance will be affected by business, economic, financial and other factors, including potential changes in state and federal government payment rates for healthcare, customer demand, success of our marketing efforts, pressures from competitors, and the state of the economy, including the state of financial and credit markets, as well as many unforeseen factors.

Commitment and Contingencies

Governmental Regulations

Laws and regulations governing the Medicare, Medicaid and other federal healthcare programs are complex and subject to interpretation. Management believes that it is following all applicable laws and regulations in all material respects. However, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusions from the Medicare, Medicaid, and other federal healthcare programs.

Table of Contents

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

Market risk represents the potential economic loss arising from adverse changes in the fair value of financial instruments. Currently, our exposure to market risk relates primarily to our fixed–income and equity portfolios. These investment portfolios are exposed primarily to, but not limited to, interest rate risk, credit risk, equity price risk, and concentration risk. We also have exposure to market risk that includes our cash and cash equivalents. The Company's senior management has established comprehensive risk management policies and procedures to manage these market risks.

Interest Rate Risk

The fair values of our fixed–income investments fluctuate in response to changes in market interest rates. Increases and decreases in prevailing interest rates generally translate into decreases and increases, respectively, in the fair values of those instruments. Additionally, the fair values of interest rate sensitive instruments may be affected by the creditworthiness of the issuer, prepayment options, the liquidity of the instrument and other general market conditions. At March 31, 2024, we have available for sale marketable debt securities in the amount of $124,316,000. The fixed maturity portfolio is comprised of investments with primarily short–term and intermediate–term maturities. The fixed maturity portfolio allows our insurance company subsidiaries to achieve an adequate risk–adjusted return while maintaining sufficient liquidity to meet obligations.

Our cash and cash equivalents consist of highly liquid investments with a maturity of less than three months when purchased. As a result of the short–term nature of our cash instruments, a hypothetical 1% change in interest rates would have minimal impact on our future earnings and cash flows related to these instruments.

We do not currently use any derivative instruments to hedge our interest rate exposure. We have not used derivative instruments for trading purposes and the use of such instruments in the future would be subject to approvals by the Investment Committee of the Board of Directors.

Credit Risk

Credit risk is managed by diversifying the fixed maturity portfolio to avoid concentrations in any single industry group or issuer and by limiting investments in securities with lower credit ratings.

Equity Price and Concentration Risk

Our marketable equity securities are recorded at their fair market value based on quoted market prices. Thus, there is exposure to equity price risk, which is the potential change in fair value due to a change in quoted market prices. At March 31, 2024, the fair value of our marketable equity securities is approximately $152,656,000. Of the $152.7 million equity securities portfolio, our investment in NHI comprises approximately $102.5 million, or 67.1%, of the total fair value. We manage our exposure to NHI by closely monitoring the financial condition, performance, and outlook of the company. Hypothetically, a 10% change in quoted market prices would result in a related increase or decrease in the fair value of our equity investments of approximately $15.3 million. At March 31, 2024, our equity securities had net unrealized gains of $98.0 million. Of the $98.0 million of unrealized gains, $77.7 million is related to our investment in NHI.

Item 4.

Controls and Procedures.

As of March 31, 2024, an evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2024.

During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings.

For a discussion of prior, current, and pending litigation of material significance to NHC, please see Note 16 of this Form 10–Q.

Item 1A.

Risk Factors.

During the three months ended March 31, 2024, there were no material changes to the risk factors that were disclosed in Item 1A of National HealthCare Corporation’s Annual Report on Form 10-K for the year ended December 31, 2023.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

Not applicable

Item 3.

Defaults Upon Senior Securities.

None

Item 4.

Mine Safety Disclosures.

Not applicable

Item 5.

Other Information.

None

Table of Contents

Item 6.

Exhibits.

(a) List of exhibits

EXHIBIT INDEX

Exhibit No.		Description

3.1		Certificate of Incorporation of National HealthCare Corporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s registration statement on Form S-4 (File No. 333-37185) dated October 3, 1997.)

3.2		Certificate of Amendment to the Certificate of Incorporation of National HealthCare Corporation (Incorporated by reference to Exhibit 3.5 to the quarterly report on Form 10-Q filed on August 3, 2017.)

3.3		Certificate of Designation Series B Junior Participating Preferred Stock (Incorporated by reference to Exhibit 3.1 to the Registrant’s registration statement on Form 8-A, dated August 3, 2007.)

3.4		Restated Bylaws as amended February 14, 2013 (Incorporated by reference to Exhibit 3.5 to the quarterly report on Form 10-Q filed on May 8, 2013.)

4.1		Form of Common Stock (Incorporated by reference to Exhibit 4.1 to the quarterly report on Form 10-Q filed on August 3, 2017.)

10.1		Amendment No. 9 to Master Agreement to Lease between National Health Investors, Inc. and National HealthCare Corporation (Incorporated by reference to Exhibit 10.1 to the quarterly report on Form 10-Q filed on November 3, 2022.)

10.2		Amendment No. 10 to Master Agreement to Lease between National Health Investors, Inc. and National HealthCare Corporation (Incorporated by reference to Exhibit 10.2 to the quarterly report on Form 10-Q filed on November 3, 2022.)

31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

31.2		Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

32		Certification pursuant to 18 U.S.C. Section 1350 by Chief Executive Officer and Chief Financial Officer

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive File (embedded within the Inline XBRL document and include in Exhibit 101)

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NATIONAL HEALTHCARE CORPORATION
	(Registrant)

Date: May 9, 2024	/s/ Stephen F. Flatt
	Stephen F. Flatt
	Chief Executive Officer


Date: May 9, 2024	/s/ Brian F. Kidd
	Brian F. Kidd
	Senior Vice President and Chief Financial
	Officer

EXHIBIT 31.1

CERTIFICATION

I, Stephen F. Flatt, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of National HealthCare Corporation;

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function);

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 9, 2024

	/s/ Stephen F. Flatt
	Stephen F. Flatt
	Chief Executive Officer

EXHIBIT 31.2

CERTIFICATION

I, Brian F. Kidd, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of National HealthCare Corporation;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 9, 2024

	/s/ Brian F. Kidd
	Brian F. Kidd
	Senior Vice President and Chief Financial Officer

Exhibit 32

Certification of Quarterly Report on Form 10-Q

of National HealthCare Corporation

For the Quarter Ended March 31, 2024

The undersigned hereby certify, pursuant to 18 U.S.C. Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned's best knowledge and belief, the Quarterly Report on Form 10-Q for National HealthCare Corporation ("Issuer") for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"):

(a)

fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Issuer.

This Certification accompanies the Quarterly Report on Form 10-Q of the Issuer for the quarterly period ended March 31, 2024.

This Certification is executed as of May 9, 2024.

	/s/Stephen F. Flatt
	Stephen F. Flatt
	Chief Executive Officer


	/s/ Brian F. Kidd
	Brian F. Kidd
	Senior Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2024	May 01, 2024
Document Information [Line Items]
Entity Central Index Key	0001047335
Entity Registrant Name	NATIONAL HEALTHCARE CORP
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-13489
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	52-2057472
Entity Address, Address Line One	100 E. Vine Street
Entity Address, City or Town	Murfreesboro
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37130
City Area Code	615
Local Phone Number	890–2020
Title of 12(b) Security	Common, $0.01 par value
Trading Symbol	NHC
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		15,399,724

Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Net patient revenues	$ 285,823,000	$ 258,007,000
Other revenues	11,353,000	11,556,000
Net operating revenues	297,176,000	269,563,000
Costs and expenses:
Salaries, wages, and benefits	183,138,000	167,824,000
Other operating	77,429,000	71,489,000
Facility rent	10,348,000	10,092,000
Depreciation and amortization	10,586,000	10,048,000
Interest	46,000	98,000
Total costs and expenses	281,547,000	259,551,000
Income from operations	15,629,000	10,012,000
Other income:
Non–operating income	5,685,000	4,323,000
Unrealized gains on marketable equity securities	14,399,000	1,386,000
Income before income taxes	35,713,000	15,721,000
Income tax provision	(9,462,000)	(4,436,000)
Net income	26,251,000	11,285,000
Net (income)/loss attributable to noncontrolling interest	(38,000)	438,000
Net income attributable to National HealthCare Corporation	$ 26,213,000	$ 11,723,000
Earnings per share attributable to National HealthCare Corporation stockholders:
Basic (in dollars per share)	$ 1.71	$ 0.76
Diluted (in dollars per share)	$ 1.69	$ 0.76
Basic (in shares)	15,350,240	15,337,423
Diluted (in shares)	15,505,096	15,356,335
Dividends declared per common share (in dollars per share)	$ 0.59	$ 0.57

Interim Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net income	$ 26,251	$ 11,285
Other comprehensive income/(loss):
Unrealized gains/(losses) on investments in marketable debt securities	(472)	1,958
Reclassification adjustment for realized gains on sales of marketable debt securities	(10)	0
Income tax (expense)/benefit related to items of other comprehensive income	45	(279)
Other comprehensive income/(loss), net of tax	(437)	1,679
Net (income)/loss attributable to noncontrolling interest	(38)	438
Comprehensive income attributable to National HealthCare Corporation	$ 25,776	$ 13,402

Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 93,982,000	$ 107,076,000
Restricted cash and cash equivalents, current portion	26,010,000	17,725,000
Marketable equity securities	123,040,000	111,117,000
Marketable debt securities	484,000	5,427,000
Restricted marketable equity securities	29,616,000	26,779,000
Restricted marketable debt securities, current portion	4,790,000	12,822,000
Accounts receivable	125,664,000	108,545,000
Inventories	6,763,000	7,386,000
Prepaid expenses and other assets	6,750,000	8,855,000
Notes receivable	487,000	503,000
Total current assets	417,586,000	406,235,000
Property and Equipment:
Property and equipment, at cost	1,065,543,000	1,101,681,000
Accumulated depreciation and amortization	(576,845,000)	(608,352,000)
Net property and equipment	488,698,000	493,329,000
Other Assets:
Restricted cash and cash equivalents, less current portion	1,140,000	1,167,000
Restricted marketable debt securities, less current portion	119,042,000	109,478,000
Deposits and other assets	13,738,000	14,786,000
Operating lease right-of-use assets	87,356,000	94,201,000
Goodwill	168,295,000	168,295,000
Intangible assets	7,038,000	7,038,000
Investments in unconsolidated companies	16,747,000	16,267,000
Total other assets	413,356,000	411,232,000
Total assets	1,319,640,000	1,310,796,000
Current Liabilities:
Trade accounts payable	20,697,000	19,194,000
Finance lease obligations, current portion	0	860,000
Operating lease liabilities, current portion	29,733,000	29,352,000
Accrued payroll	64,156,000	84,110,000
Amounts due to third party payors	19,988,000	18,369,000
Accrued risk reserves, current portion	30,800,000	30,549,000
Other current liabilities	24,302,000	22,991,000
Contract liabilities	7,667,000	0
Dividends payable	9,086,000	9,051,000
Total current liabilities	206,429,000	214,476,000
Operating lease liabilities, less current portion	56,004,000	63,175,000
Accrued risk reserves, less current portion	77,437,000	72,710,000
Refundable entrance fees	5,708,000	6,376,000
Deferred income taxes	19,639,000	17,200,000
Other noncurrent liabilities	27,909,000	26,379,000
Total liabilities	393,126,000	400,316,000
Equity:
Common stock, $.01 par value; 45,000,000 shares authorized; 15,399,724 and 15,350,661 shares, respectively, issued and outstanding	154,000	153,000
Capital in excess of par value	226,909,000	227,604,000
Retained earnings	704,726,000	687,599,000
Accumulated other comprehensive loss	(7,041,000)	(6,604,000)
Total National HealthCare Corporation stockholders’ equity	924,748,000	908,752,000
Noncontrolling interest	1,766,000	1,728,000
Total equity	926,514,000	910,480,000
Total liabilities and equity	$ 1,319,640,000	$ 1,310,796,000

Interim Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	45,000,000	45,000,000
Common stock, shares issued (in shares)	15,399,724	15,350,661
Common stock, shares outstanding (in shares)	15,399,724	15,350,661

Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows From Operating Activities:
Net income	$ 26,251,000	$ 11,285,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	10,586,000	10,048,000
Equity in earnings of unconsolidated investments	(67,000)	(1,535,000)
Unrealized gains on marketable equity securities	(14,399,000)	(1,386,000)
(Gains)/losses on sale of marketable securities	(344,000)	492,000
Gain on sale of unconsolidated company	(1,024,000)	0
Deferred income taxes	(2,484,000)	(331,000)
Stock–based compensation	793,000	639,000
Changes in operating assets and liabilities:
Accounts receivable	(17,119,000)	(3,148,000)
Inventories	623,000	142,000
Prepaid expenses and other assets	3,153,000	1,957,000
Operating lease obligations	55,000	(316,000)
Trade accounts payable	1,503,000	(4,018,000)
Accrued payroll	(19,954,000)	(15,800,000)
Amounts due to third party payors	1,619,000	48,000
Accrued risk reserves	4,978,000	3,157,000
Contract liabilities	7,667,000	0
Other current liabilities	1,311,000	5,407,000
Other noncurrent liabilities	1,530,000	6,554,000
Net cash provided by operating activities	9,646,000	13,857,000
Cash Flows From Investing Activities:
Purchases of property and equipment	(5,955,000)	(6,640,000)
Proceeds from sale of unconsolidated company	2,100,000	0
Investments in unconsolidated companies	(1,488,000)	0
Collections of notes receivable	16,000	2,000
Purchases of marketable securities	(8,703,000)	(10,281,000)
Proceeds from sale of marketable securities	11,615,000	15,492,000
Net cash used in investing activities	(2,415,000)	(1,427,000)
Cash Flows From Financing Activities:
Principal payments under finance lease obligations	(860,000)	(1,218,000)
Dividends paid to common stockholders	(9,051,000)	(8,748,000)
Issuance of common stock	8,412,000	0
Repurchase of common shares	(9,900,000)	(2,482,000)
Entrance fee refunds	(668,000)	(171,000)
Net cash used in financing activities	(12,067,000)	(12,619,000)
Net Decrease in Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	(4,836,000)	(189,000)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning of Period	125,968,000	74,865,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, End of Period	121,132,000	74,676,000
Balance Sheet Classifications:
Cash and cash equivalents	93,982,000	46,144,000
Restricted Cash and Cash Equivalents	27,150,000	28,532,000
Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	$ 121,132,000	$ 74,676,000

Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2022	15,357,746
Balance at Dec. 31, 2022	$ 153	$ 226,991	$ 656,664	$ (9,532)	$ 3,238	$ 877,514
Net income	0	0	11,723	0	(438)	11,285
Other comprehensive income (loss)	0	0	0	1,679	0	1,679
Stock–based compensation	$ 0	639	0	0	0	639
Shares sold – options exercised (in shares)	7,046
Shares sold – options exercised	$ 0	0	0	0	0	0
Repurchase of common shares (in shares)	(44,349)
Repurchase of common shares	$ 0	(2,482)	0	0	0	(2,482)
Dividends declared to common stockholders	$ 0	0	(8,733)	0	0	(8,733)
Balance (in shares) at Mar. 31, 2023	15,320,443
Balance at Mar. 31, 2023	$ 153	225,148	659,654	(7,853)	2,800	879,902
Balance (in shares) at Dec. 31, 2022	15,357,746
Balance at Dec. 31, 2022	$ 153	226,991	656,664	(9,532)	3,238	$ 877,514
Shares sold – options exercised (in shares)						103,481
Balance (in shares) at Dec. 31, 2023	15,350,661
Balance at Dec. 31, 2023	$ 153	227,604	687,599	(6,604)	1,728	$ 910,480
Net income	0	0	26,213	0	38	26,251
Other comprehensive income (loss)	0	0	0	(437)	0	(437)
Stock–based compensation	$ 0	793	0	0	0	$ 793
Shares sold – options exercised (in shares)	150,194					137,874
Shares sold – options exercised	$ 1	8,412	0	0	0	$ 8,413
Repurchase of common shares (in shares)	(101,131)
Repurchase of common shares	$ 0	(9,900)	0	0	0	(9,900)
Dividends declared to common stockholders	$ 0	0	(9,086)	0	0	(9,086)
Balance (in shares) at Mar. 31, 2024	15,399,724
Balance at Mar. 31, 2024	$ 154	$ 226,909	$ 704,726	$ (7,041)	$ 1,766	$ 926,514

Interim Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Dividends declared to common stockholders, per share (in dollars per share)	$ 0.59	$ 0.57

Note 1 - Description of Business

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 – Description of Business

Note 2 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

Estimates and Assumptions

Net Patient Revenues and Accounts Receivable

Other Revenues

Segment Reporting

Other Operating Expenses

General and Administrative Costs

Long-Term Leases

Property and Equipment

Business Combinations

Goodwill and Other Intangible Assets

Accrued Risk Reserves

Continuing Care Contracts

Other Noncurrent Liabilities

Noncontrolling Interest

Variable Interest Entities

Recently Issued Accounting Guidance

Note 3 - Net Patient Revenues

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

Note 3 – Net Patient Revenues

The Company disaggregates revenue from contracts with customers by service type and by payor.

Revenue by Service Type

	Three Months Ended March 31
	2024		2023
Net patient revenues:
Inpatient services	$	252,254	$	226,169
Homecare and hospice		33,569		31,838
Total net patient revenues	$	285,823	$	258,007

Revenue by Payor

Certain groups of patients receive funds to pay the cost of their care from a common source. The following table sets forth sources of net patient revenues for the periods indicated:

	Three Months Ended March 31
Source	2024		2023
Medicare		34%		36%
Managed Care		10%		11%
Medicaid		28%		27%
Private Pay and Other		28%		26%
Total		100%		100%

State Relief Supplemental Funding

Contract Liabilities

A summary of the activity related to contract liabilities follows (in thousands):

Balance at December 31, 2023	$	-
Payments received		9,881
Payments recouped		(2,214	)
Balance at March 31, 2024	$	7,667

Third Party Payors

Note 4 - Other Revenues

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Other Revenues [Text Block]

Note 4 – Other Revenues

	Three Months Ended March 31
	2024		2023
Rental income	$	5,959	$	6,043
Management and accounting services fees		4,438		4,097
Insurance services		872		1,048
Other		84		368
Total other revenues	$	11,353	$	11,556

Rental Income

Management Fees from National Health Corporation

Insurance Services

Note 5 - Non-operating Income

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Other Nonoperating Income and Expense [Text Block]

Note 5 – Non–Operating Income

Non–operating income is comprised of the following (in thousands):

	Three Months Ended March 31
	2024		2023
Dividends and net realized gains and losses on sales of securities	$	2,056	$	1,233
Interest income		2,538		1,555
Equity in earnings of unconsolidated investments		67		1,535
Gain on sale of unconsolidated company		1,024		-
Total non-operating income	$	5,685	$	4,323

Gain on sale of unconsolidated company

Note 6 - Business Segments

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 6 – Business Segments

The following table sets forth the Company’s unaudited interim condensed consolidated statements of operations by business segment (in thousands):

	Three Months Ended March 31, 2024
	Inpatient Services		Homecare and Hospice		All Other			Total
Revenues:
Net patient revenues	$	252,254	$	33,569	$	-		$	285,823
Other revenues		15		-		11,338			11,353
Net operating revenues		252,269		33,569		11,338			297,176

Costs and expenses:
Salaries, wages, and benefits		150,890		21,009		11,239			183,138
Other operating		68,683		5,972		2,774			77,429
Rent		8,112		566		1,670			10,348
Depreciation and amortization		9,630		187		769			10,586
Interest		46		-		-			46
Total costs and expenses		237,361		27,734		16,452			281,547

Income/(loss) from operations		14,908		5,835		(5,114	)		15,629
Non-operating income		-		-		5,685			5,685
Unrealized gains on marketable equity securities		-		-		14,399			14,399

Income before income taxes	$	14,908	$	5,835	$	14,970		$	35,713

	Three Months Ended March 31, 2023
	Inpatient Services		Homecare and Hospice		All Other			Total
Revenues:
Net patient revenues	$	226,169	$	31,838	$	-		$	258,007
Other revenues		271		-		11,285			11,556
Net operating revenues		226,440		31,838		11,285			269,563

Costs and expenses:
Salaries, wages, and benefits		138,939		20,244		8,641			167,824
Other operating		62,264		5,499		3,726			71,489
Rent		8,168		558		1,366			10,092
Depreciation and amortization		9,117		185		746			10,048
Interest		98		-		-			98
Total costs and expenses		218,586		26,486		14,479			259,551

Income/(loss) from operations		7,854		5,352		(3,194	)		10,012
Non-operating income		-		-		4,323			4,323
Unrealized gains on marketable equity securities		-		-		1,386			1,386

Income before income taxes	$	7,854	$	5,352	$	2,515		$	15,721

Note 7 - Long-term Leases

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Lessee, Operating and Finance Leases [Text Block]

Note 7 – Long-Term Leases

Operating Leases

Minimum Lease Payments

The following table summarizes the maturity of our operating lease liabilities as of March 31, 2024 (in thousands):

	Operating Leases
2025	$	34,351
2026		33,590
2027		24,933
2028		493
2029		207
Thereafter		21
Total minimum lease payments		93,595
Less: amounts representing interest		(7,858	)
Present value of future minimum lease payments		85,737
Less: current portion		(29,733	)
Noncurrent lease liabilities	$	56,004

Note 8 - Earnings Per Share

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 8 – Earnings per Share

	Three Months Ended March 31
	2024		2023
Basic:
Weighted average common shares outstanding		15,350,240		15,337,423
Net income attributable to National HealthCare Corporation	$	26,213	$	11,723
Earnings per common share, basic	$	1.71	$	0.76

Diluted:
Weighted average common shares outstanding		15,350,240		15,337,423
Effects of dilutive instruments		154,856		18,912
Weighted average common shares outstanding		15,505,096		15,356,335

Net income attributable to National HealthCare Corporation	$	26,213	$	11,723
Earnings per common share, diluted	$	1.69	$	0.76

Note 9 - Investments in Marketable Securities

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Note 9 – Investments in Marketable Securities

Marketable securities consist of the following (in thousands):

	March 31, 2024				December 31, 2023
	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Investments available for sale:
Marketable equity securities	$	30,176	$	123,040	$	30,176	$	111,117
Corporate debt securities		494		484		2,497		2,441
U.S. Treasury securities		-		-		2,990		2,986
Restricted investments available for sale:
Marketable equity securities		24,495		29,616		24,134		26,779
Corporate debt securities		61,488		59,398		59,586		57,731
Asset-based securities		19,026		17,438		19,388		17,659
U.S. Treasury securities		47,323		43,004		46,771		42,863
State and municipal securities		4,079		3,992		4,106		4,047
	$	187,081	$	276,972	$	189,648		265,623

Included in the marketable equity securities are the following (in thousands, except share amounts):

March 31, 2024

December 31, 2023

Cost

Fair

Value

Cost

Fair

Value

NHI Common Stock

1,630,642

24,734

102,453

1,630,642

24,734

91,071

The amortized cost and estimated fair value of debt securities classified as available for sale, by contractual maturity, are as follows (in thousands):

	March 31, 2024				December 31, 2023
	Cost		Fair Value		Cost		Fair Value
Maturities:
Within 1 year	$	21,299	$	20,785	$	19,664	$	19,328
1 to 5 years		77,738		73,370		81,517		77,118
6 to 10 years		32,012		28,925		33,515		30,802
Over 10 years		1,361		1,236		642		479
	$	132,410	$	124,316	$	135,338	$	127,727

Note 10 - Fair Value Measurements

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note 10 – Fair Value Measurements

	Level 1 – The valuation is based on quoted prices in active markets for identical instruments.
	Level 2 – The valuation is based on observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model–based valuation techniques for which all significant assumptions are observable in the market.
	Level 3 – The valuation is based on unobservable inputs that are supported by minimal or no market activity and that are significant to the fair value of the instrument. Level 3 valuations are typically performed using pricing models, discounted cash flow methodologies, or similar techniques that incorporate management’s own estimates of assumptions that market participants would use in pricing the instrument, or valuations that require significant management judgment or estimation.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.

The following table summarizes fair value measurements by level at March 31, 2024 and December 31, 2023 for assets and liabilities measured at fair value on a recurring basis (in thousands):

	Fair Value Measurements Using
March 31, 2024	Fair Value		Quoted Prices in Active Markets For Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$	93,982	$	93,982	$	–	$	–
Restricted cash and cash equivalents		27,150		27,150		–		–
Marketable equity securities		152,656		152,656		–		–
Corporate debt securities		59,882		42,611		17,271		–
Asset–backed securities		17,438		–		16,961		477
U.S. Treasury securities		43,004		43,004		–		–
State and municipal securities		3,992		–		3,992		–
Total financial assets	$	398,104	$	359,403	$	38,224	$	477

	Fair Value Measurements Using
December 31, 2023	Fair Value		Quoted Prices in Active Markets For Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$	107,076	$	107,076	$	–	$	–
Restricted cash and cash equivalents		18,892		18,892		–		–
Marketable equity securities		137,896		137,896		–		–
Corporate debt securities		60,171		42,860		17,311		–
Asset–backed securities		17,659		–		17,210		449
U.S. Treasury securities		45,850		45,850		–		–
State and municipal securities		4,047		–		4,047		–
Total financial assets	$	391,591	$	352,574	$	38,568	$	449

Note 11 - Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

Note 11 – Goodwill and Other Intangible Assets

At March 31, 2024, the following table represents the activity related to our goodwill by segment (in thousands):

	Inpatient Services		Homecare and Hospice		All Other		Total
January 1, 2024	$	3,741	$	164,554	$	–	$	168,295
Additions		–		–		–		–
March 31, 2024	$	3,741	$	164,554	$	–	$	168,295

We also have recorded indefinite-lived intangible assets that consist of trade names ($4,340,000) and certificates of need and licenses ($2,698,000).

Note 12 - Stock Repurchase Program

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Treasury Stock [Text Block]

Note 12 - Stock Repurchase Program

Note 13 - Stock-based Compensation

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

Note 13 – Stock–Based Compensation

Stock Options

The following table summarizes the significant assumptions used to value the options granted for the three months ended March 31, 2024 and for the year ended December 31, 2023.

	March 31, 2024		December 31, 2023
Risk–free interest rate		4.33%		4.52%
Expected volatility		24.1%		29.3%
Expected life, in years		2.9		2.9
Expected dividend yield		2.64%		4.41%

The following table summarizes our outstanding stock options for the three months ended March 31, 2024 and for the year ended December 31, 2023.

	Number of Shares			Weighted Average Exercise Price		Aggregate Intrinsic Value
Options outstanding at January 1, 2023		445,144		$	66.62	$	–
Options granted		299,278			54.44		–
Options exercised		(103,481	)		64.72		–
Options cancelled		(52,407	)		60.58		–
Options outstanding at December 31, 2023		588,534			61.30		–
Options granted		245,726			94.07		–
Options exercised		(137,874	)		60.95		–
Options outstanding at March 31, 2024		696,386		$	72.93	$	15,025,015

Options exercisable at March 31, 2024		174,105		$	68.48	$	4,531,876

Options Outstanding March 31, 2024	Exercise Prices			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years
377,405	53.94	-	69.19		58.92		3.5
318,981	71.64	-	94.10		89.51		4.0
696,386					72.93		3.7

Note 14 - Income Taxes

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Income Tax Disclosure [Text Block]

Note 14 – Income Taxes

The Company's income tax provision as a percentage of our income before income taxes was 26.5% and 28.2% for the three months ended March 31, 2024 and 2023, respectively.

The Company is no longer subject to U.S. federal and state examinations by tax authorities for years before 2020 (with certain state exceptions).

Note 15 - Credit Facility - Schedule of Long-Term Debt Instruments

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Schedule of Long-Term Debt Instruments [Table Text Block]

Note 15 – Credit Facility

As of March 31, 2024, the Company had no outstanding balance on the credit facility. We do not expect to renew this credit facility upon its maturity date.

Note 16 - Contingencies and Commitments

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Note 16 – Contingencies and Commitments

Accrued Risk Reserves

Workers’ Compensation

General and Professional Liability Insurance and Lawsuits

Qui Tam Litigation

Governmental Regulations

Insider Trading Arrangements

3 Months Ended

Mar. 31, 2024

Insider Trading Arr Line Items

Material Terms of Trading Arrangement [Text Block]

Item 5.

Other Information.

None

Rule 10b5-1 Arrangement Adopted [Flag]

false

Non-Rule 10b5-1 Arrangement Adopted [Flag]

false

Rule 10b5-1 Arrangement Terminated [Flag]

false

Non-Rule 10b5-1 Arrangement Terminated [Flag]

false

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The unaudited interim condensed consolidated financial statements to which these notes are attached include all normal, recurring adjustments which are necessary to fairly present the financial position, results of operations and cash flows of NHC. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by NHC. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to NHC and the noncontrolling interest in its consolidated statements of operations. We assume that users of these interim financial statements have read or have access to the audited December 31, 2023 consolidated financial statements and that the adequacy of additional disclosure needed for a fair presentation, except in regard to material contingencies, may be determined in that context. Accordingly, footnotes and other disclosures which would substantially duplicate the disclosure contained in our most recent annual report to stockholders have been omitted. This interim financial information is not necessarily indicative of the results that may be expected for a full year for a variety of reasons.
Use of Estimates, Policy [Policy Text Block]	Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and could cause our reported net income to vary significantly from period to period.
Revenue [Policy Text Block]	Net Patient Revenues and Accounts Receivable Net patient revenues are derived from services rendered to patients for skilled and intermediate nursing, rehabilitation therapy, assisted living and independent living, home health care services, hospice services, and behavioral health services. Net patient revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient services. These amounts are due from patients, governmental programs, and other third-party payors, and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. The Company recognizes revenue as its performance obligations are completed. Routine services are treated as a single performance obligation satisfied over time as services are rendered. These routine services represent a bundle of services that are not capable of being distinct. The performance obligations are satisfied over time as the patient simultaneously receives and consumes the benefits of the healthcare services provided. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time when those services are rendered. Contract liabilities are recorded for payments the Company receives in which performance obligations have not been completed. The Company determines the transaction price based on established billing rates reduced by explicit price concessions provided to third party payors. Explicit price concessions are based on contractual agreements and historical experience. The Company considers the patient's ability and intent to pay the amount of consideration upon admission. Credit losses are recorded as bad debt expense, which is included as a component of other operating expenses in the interim condensed consolidated statements of operations. Bad debt expense was $2,471,000 and $1,811,000 for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, and December 31, 2023, the Company has recorded allowance for doubtful accounts of $9,174,000 and $8,054,000, respectively, as our best estimate of expected losses inherent in the accounts receivable balance.
Revenue Recognition for Alternative Revenue Programs, Policy [Policy Text Block]	Other Revenues Other revenues include revenues from the provision of insurance services, management and accounting services to other long–term care providers, and rental income. Our insurance revenues consist of premiums that are generally paid in advance and then amortized into income over the policy period. We charge for management services based on a percentage of net revenues. We charge for accounting services based on a monthly fee or a fixed fee per bed of the healthcare center under contract. We record other revenues as the performance obligations are satisfied based on the terms of our contractual arrangements. We recognize rental income based on the terms of our operating leases. Under certain of our leases, we receive variable rent, which is based on the increase in revenues of a lessee over a base year. We recognize variable rent annually or monthly, as applicable, when, based on the actual revenue of the lessee is earned.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting In accordance with the provisions of Accounting Standards Codification ("ASC") 280, Segment Reporting, the Company is required to report financial and descriptive information about its reportable operating segments. The Company has two reportable operating segments: (1) inpatient services, which includes the operation of skilled nursing facilities, assisted and independent living facilities, and behavioral health hospitals, and (2) homecare and hospice services. The Company also reports an “all other” category that includes revenues from rental income, management and accounting services fees, insurance services, and costs of the corporate office. See Note 6 for further disclosure of the Company’s operating segments.
Other Operating Expenses Policy [Policy Text Block]	Other Operating Expenses Other operating expenses include the costs of care and services that we provide to the residents of our facilities and the costs of maintaining our facilities. Our primary patient care costs include drugs, medical supplies, purchased professional services, food, and professional liability insurance and licensing fees. The primary facility costs include utilities and property insurance.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	General and Administrative Costs With the Company being a healthcare provider, the majority of our expenses are "cost of revenue" items. Costs that could be classified as "general and administrative" by the Company would include its corporate office costs, excluding stock-based compensation, which were $6,164,000 and $5,653,000 for the three months ended March 31, 2024 and 2023, respectively.
Lessee, Leases [Policy Text Block]	Long-Term Leases The Company’s lease portfolio primarily consists of operating real estate leases for certain skilled nursing facilities, assisted and independent living facilities, homecare and hospice offices, and pharmacy warehouses. The original terms of the leases typically range from two to fifteen years. Several of the real estate leases include renewal options which vary in length and may not include specific rent renewal amounts. We determine if an arrangement is a lease at inception of a contract. We determine the lease term by assuming exercise of renewal options that are reasonably certain. The Company records right-of-use assets and liabilities for non-cancelable real estate operating leases with original or remaining lease terms in excess of one year. Leases with a lease term of 12 months or less at inception are not recorded and are expensed on a straight-line basis over the lease term. We recognize lease components and non-lease components together and not as separate parts of a lease for real estate leases. Operating lease right-of-use assets and liabilities are recorded at the present value of the lease payments over the lease term. The present value of the lease payments are discounted using the incremental borrowing rate associated with each lease. The variable components of the lease payment that fluctuate with the operations of a health facility are not included in determining the right-of-use assets and lease liabilities. Rather, these variable components are expensed as incurred.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost. Depreciation is provided by the straight-line method over the expected useful lives of the assets estimated as follows: buildings and improvements, 20-40 years and equipment and furniture, 3-15 years. Leasehold improvements are amortized over periods that do not exceed the non-cancelable respective lease terms using the straight-line method.
Business Combinations Policy [Policy Text Block]	Business Combinations We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, Business Combinations. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. In determining the fair value of identifiable assets, we use various valuation techniques. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth, and discount rates.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and Other Intangible Assets Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is subject to an annual impairment test. We perform our annual goodwill impairment assessment on the first day of the fourth quarter. Tests are performed more frequently if events occur, or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. The Company’s indefinite-lived intangible assets consist of trade names and certificates of need and licenses. The Company reviews indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Liability Reserve Estimate, Policy [Policy Text Block]	Accrued Risk Reserves We are self–insured for risks related to workers’ compensation and general and professional liability insurance. We have two wholly–owned limited purpose insurance companies that insure these risks. The accrued risk reserves include a liability for reported claims and estimates for incurred but unreported claims. Our policy is to engage an external, independent actuary to assist in estimating our exposure for claims obligations (for both asserted and unasserted claims). We reassess our accrued risk reserves on a quarterly basis. Professional liability remains an area of particular concern to us. The long-term care industry has seen an increase in personal injury/wrongful death claims based on alleged negligence by skilled nursing facilities and their employees in providing care to residents. The Company has been, and continues to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims could have a material adverse effect on our consolidated financial position, results of operations and cash flows. It is also possible that future events could cause us to make significant adjustments or revisions to these reserve estimates and cause our reported net income to vary significantly from period to period. We are principally self-insured for incidents occurring in all centers owned or leased by us. The coverages include both primary policies and excess policies. In all years, settlements, if any, in excess of available insurance policy limits and our own reserves would be expensed by us.
Continuing Care Contracts and Refundable Entrance Fees, Policy [Policy Text Block]	Continuing Care Contracts We have one continuing care retirement center (“CCRC”) within our operations. Residents at this retirement center may enter into continuing care contracts with us. The contracts provide that 10% of the resident entry fee becomes non-refundable upon occupancy, and the remaining refundable portion of the entry fee is calculated using the lesser of the price at which the apartment is re-assigned or 90% of the original entry fee, plus 40% of any appreciation if the apartment value exceeds the original resident’s entry fee. Non-refundable fees are included as a component of the transaction price and are amortized into revenue over the actuarily determined remaining life of the resident, which is the expected period of occupancy by the resident. We pay the refundable portion of our entry fees to residents when they relocate from our community and the apartment is re-occupied. Refundable entrance fees are not included as part of the transaction price and are classified as noncurrent liabilities in our consolidated balance sheets. We also annually estimate the present value of the cost of future services and the use of facilities to be provided to the current CCRC residents and compare that amount with the balance of non-refundable deferred revenue from entrance fees received. If the present value of the cost of future services exceeds the related anticipated revenues, a liability is recorded with a corresponding charge to income. As of March 31, 2024, and December 31, 2023, we have recorded a future service obligation liability in the amount of $1,606,000. This obligation is reflected within other noncurrent liabilities in the interim condensed consolidated balance sheets.
Other Noncurrent Liabilities [Policy Text Block]	Other Noncurrent Liabilities Other noncurrent liabilities include reserves primarily related to various uncertain income tax positions, deferred revenue, and obligations to provide future services to our CCRC residents. Deferred revenue includes the deferred gain on the sale of assets to National Health Corporation (“National”) and the non-refundable portion (10%) of CCRC entrance fees being amortized over the remaining life expectancies of the residents. Other noncurrent liabilities also include funds received related to the Employee Retention Credit ("ERC"), a refundable tax credit for businesses that sustained a partial suspension of operations limiting commerce due to COVID-19 or had significant declines in gross receipts during 2020 and 2021.
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Noncontrolling Interest The noncontrolling interest in a subsidiary is presented within total equity in the Company's interim condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to NHC in its interim condensed consolidated statements of operations. The Company’s earnings per share is calculated based on net income attributable to NHC’s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of the subsidiary earnings, contributions, and distributions.
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	Variable Interest Entities We have equity interests in unconsolidated limited liability companies that operate various post-acute and senior healthcare businesses. We analyze our investments in these limited liability companies to determine if the company is considered a variable interest entity (“VIE”) and would require consolidation. To the extent that we own interests in a VIE and we (i) have the power to direct the activities of the VIE and (ii) have the obligation or rights to absorb the VIE's losses or receive its benefits, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary. The Company's maximum exposure to losses in its investments in unconsolidated VIEs cannot be quantified and may or may not be limited to its investment in the unconsolidated VIE. The investments in unconsolidated VIEs are classified as “investments in unconsolidated companies” in the interim condensed consolidated balance sheets.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Guidance In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvement to Reportable Segment Disclosures.” The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit and loss, and contain other disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2023, which will be the Company's fiscal year 2024, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact this standard will have on our disclosures.

Note 3 - Net Patient Revenues (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended March 31
	2024		2023
Net patient revenues:
Inpatient services	$	252,254	$	226,169
Homecare and hospice		33,569		31,838
Total net patient revenues	$	285,823	$	258,007

	Three Months Ended March 31
Source	2024		2023
Medicare		34%		36%
Managed Care		10%		11%
Medicaid		28%		27%
Private Pay and Other		28%		26%
Total		100%		100%

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

Balance at December 31, 2023	$	-
Payments received		9,881
Payments recouped		(2,214	)
Balance at March 31, 2024	$	7,667

Note 4 - Other Revenues (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Schedule of Other Revenues [Table Text Block]

	Three Months Ended March 31
	2024		2023
Rental income	$	5,959	$	6,043
Management and accounting services fees		4,438		4,097
Insurance services		872		1,048
Other		84		368
Total other revenues	$	11,353	$	11,556

Note 5 - Non-operating Income (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Schedule of Other Nonoperating Income, by Component [Table Text Block]

	Three Months Ended March 31
	2024		2023
Dividends and net realized gains and losses on sales of securities	$	2,056	$	1,233
Interest income		2,538		1,555
Equity in earnings of unconsolidated investments		67		1,535
Gain on sale of unconsolidated company		1,024		-
Total non-operating income	$	5,685	$	4,323

Note 6 - Business Segments (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended March 31, 2024
	Inpatient Services		Homecare and Hospice		All Other			Total
Revenues:
Net patient revenues	$	252,254	$	33,569	$	-		$	285,823
Other revenues		15		-		11,338			11,353
Net operating revenues		252,269		33,569		11,338			297,176

Costs and expenses:
Salaries, wages, and benefits		150,890		21,009		11,239			183,138
Other operating		68,683		5,972		2,774			77,429
Rent		8,112		566		1,670			10,348
Depreciation and amortization		9,630		187		769			10,586
Interest		46		-		-			46
Total costs and expenses		237,361		27,734		16,452			281,547

Income/(loss) from operations		14,908		5,835		(5,114	)		15,629
Non-operating income		-		-		5,685			5,685
Unrealized gains on marketable equity securities		-		-		14,399			14,399

Income before income taxes	$	14,908	$	5,835	$	14,970		$	35,713

	Three Months Ended March 31, 2023
	Inpatient Services		Homecare and Hospice		All Other			Total
Revenues:
Net patient revenues	$	226,169	$	31,838	$	-		$	258,007
Other revenues		271		-		11,285			11,556
Net operating revenues		226,440		31,838		11,285			269,563

Costs and expenses:
Salaries, wages, and benefits		138,939		20,244		8,641			167,824
Other operating		62,264		5,499		3,726			71,489
Rent		8,168		558		1,366			10,092
Depreciation and amortization		9,117		185		746			10,048
Interest		98		-		-			98
Total costs and expenses		218,586		26,486		14,479			259,551

Income/(loss) from operations		7,854		5,352		(3,194	)		10,012
Non-operating income		-		-		4,323			4,323
Unrealized gains on marketable equity securities		-		-		1,386			1,386

Income before income taxes	$	7,854	$	5,352	$	2,515		$	15,721

Note 7 - Long-term Leases (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Lessee, Lease, Liability, Maturity [Table Text Block]

	Operating Leases
2025	$	34,351
2026		33,590
2027		24,933
2028		493
2029		207
Thereafter		21
Total minimum lease payments		93,595
Less: amounts representing interest		(7,858	)
Present value of future minimum lease payments		85,737
Less: current portion		(29,733	)
Noncurrent lease liabilities	$	56,004

Note 8 - Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended March 31
	2024		2023
Basic:
Weighted average common shares outstanding		15,350,240		15,337,423
Net income attributable to National HealthCare Corporation	$	26,213	$	11,723
Earnings per common share, basic	$	1.71	$	0.76

Diluted:
Weighted average common shares outstanding		15,350,240		15,337,423
Effects of dilutive instruments		154,856		18,912
Weighted average common shares outstanding		15,505,096		15,356,335

Net income attributable to National HealthCare Corporation	$	26,213	$	11,723
Earnings per common share, diluted	$	1.69	$	0.76

Note 9 - Investments in Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Marketable Securities [Table Text Block]

	March 31, 2024				December 31, 2023
	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Investments available for sale:
Marketable equity securities	$	30,176	$	123,040	$	30,176	$	111,117
Corporate debt securities		494		484		2,497		2,441
U.S. Treasury securities		-		-		2,990		2,986
Restricted investments available for sale:
Marketable equity securities		24,495		29,616		24,134		26,779
Corporate debt securities		61,488		59,398		59,586		57,731
Asset-based securities		19,026		17,438		19,388		17,659
U.S. Treasury securities		47,323		43,004		46,771		42,863
State and municipal securities		4,079		3,992		4,106		4,047
	$	187,081	$	276,972	$	189,648		265,623

Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]

March 31, 2024

December 31, 2023

Cost

Fair

Value

Cost

Fair

Value

NHI Common Stock

1,630,642

24,734

102,453

1,630,642

24,734

91,071

Investments Classified by Contractual Maturity Date [Table Text Block]

	March 31, 2024				December 31, 2023
	Cost		Fair Value		Cost		Fair Value
Maturities:
Within 1 year	$	21,299	$	20,785	$	19,664	$	19,328
1 to 5 years		77,738		73,370		81,517		77,118
6 to 10 years		32,012		28,925		33,515		30,802
Over 10 years		1,361		1,236		642		479
	$	132,410	$	124,316	$	135,338	$	127,727

Note 10 - Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value Measurements Using
March 31, 2024	Fair Value		Quoted Prices in Active Markets For Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$	93,982	$	93,982	$	–	$	–
Restricted cash and cash equivalents		27,150		27,150		–		–
Marketable equity securities		152,656		152,656		–		–
Corporate debt securities		59,882		42,611		17,271		–
Asset–backed securities		17,438		–		16,961		477
U.S. Treasury securities		43,004		43,004		–		–
State and municipal securities		3,992		–		3,992		–
Total financial assets	$	398,104	$	359,403	$	38,224	$	477

	Fair Value Measurements Using
December 31, 2023	Fair Value		Quoted Prices in Active Markets For Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$	107,076	$	107,076	$	–	$	–
Restricted cash and cash equivalents		18,892		18,892		–		–
Marketable equity securities		137,896		137,896		–		–
Corporate debt securities		60,171		42,860		17,311		–
Asset–backed securities		17,659		–		17,210		449
U.S. Treasury securities		45,850		45,850		–		–
State and municipal securities		4,047		–		4,047		–
Total financial assets	$	391,591	$	352,574	$	38,568	$	449

Note 11 - Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Schedule of Goodwill [Table Text Block]

	Inpatient Services		Homecare and Hospice		All Other		Total
January 1, 2024	$	3,741	$	164,554	$	–	$	168,295
Additions		–		–		–		–
March 31, 2024	$	3,741	$	164,554	$	–	$	168,295

Note 13 - Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	March 31, 2024		December 31, 2023
Risk–free interest rate		4.33%		4.52%
Expected volatility		24.1%		29.3%
Expected life, in years		2.9		2.9
Expected dividend yield		2.64%		4.41%

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Shares			Weighted Average Exercise Price		Aggregate Intrinsic Value
Options outstanding at January 1, 2023		445,144		$	66.62	$	–
Options granted		299,278			54.44		–
Options exercised		(103,481	)		64.72		–
Options cancelled		(52,407	)		60.58		–
Options outstanding at December 31, 2023		588,534			61.30		–
Options granted		245,726			94.07		–
Options exercised		(137,874	)		60.95		–
Options outstanding at March 31, 2024		696,386		$	72.93	$	15,025,015

Options exercisable at March 31, 2024		174,105		$	68.48	$	4,531,876

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Options Outstanding March 31, 2024	Exercise Prices			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years
377,405	53.94	-	69.19		58.92		3.5
318,981	71.64	-	94.10		89.51		4.0
696,386					72.93		3.7

Note 1 - Description of Business (Details Textual)	Mar. 31, 2024
Number of Skilled Nursing Centers	65
Number of Beds	8,421
Number of Assisted Living Facilities	24
Number of Independent Living Facilities	5
Number of Behavioral Health Hospitals	3
Number of Homecare Programs	35
Number of Hospice Agencies	30
Number of States in which Entity Operates	8

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,471,000	$ 1,811,000
Accounts Receivable, Allowance for Credit Loss	$ 9,174,000		$ 8,054,000
Number of Reportable Segments	2
General and Administrative Expense	$ 6,164,000	$ 5,653,000
Continuing Care Retirement Communities, Refund Obligation	$ 1,606,000		$ 1,606,000
Refundable Advance Fees [Member]
Nonrefundable Resident Entry Fee Percentage	10.00%
Original Entry Fee [Member]
Refundable Resident Entry Fee Percentage	90.00%
Appreciation [Member]
Appreciation of Apartment Over Original Residents Entry Fee Percentage	40.00%
Minimum [Member]
Lessee, Operating Lease, Term of Contract (Year)	2 years
Minimum [Member] \| Building and Building Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)	20 years
Minimum [Member] \| Equipment and Furniture [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Maximum [Member]
Lessee, Operating Lease, Term of Contract (Year)	15 years
Maximum [Member] \| Building and Building Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)	40 years
Maximum [Member] \| Equipment and Furniture [Member]
Property, Plant and Equipment, Useful Life (Year)	15 years

Note 3 - Net Patient Revenues (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Revenue from Contract with Customer, Including Assessed Tax	$ 285,823,000	$ 258,007,000
Contract with Customer, Liability, Current	7,667,000		$ 0
Accounts Receivable, Allowance for Credit Loss	9,174,000		8,054,000
Medicare and Medicaid [Member]
Accounts Receivable, Allowance for Credit Loss	19,988,000		$ 18,369,000
Medicaid [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 3,462,000	$ 4,883,000

Note 3 - Net Patient Revenues - Revenue Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net patient revenues	$ 285,823	$ 258,007
Revenue, concentration percentage	100.00%	100.00%
Medicare [Member]
Revenue, concentration percentage	34.00%	36.00%
Inpatient Services [Member]
Net patient revenues	$ 252,254	$ 226,169
Managed Care [Member]
Revenue, concentration percentage	10.00%	11.00%
Homecare and Hospice [Member]
Net patient revenues	$ 33,569	$ 31,838
Medicaid [Member]
Revenue, concentration percentage	28.00%	27.00%
Private Pay and Other [Member]
Revenue, concentration percentage	28.00%	26.00%

Note 3 - Net Patient Revenues - Contract Liabilities (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)
Balance	$ 0
Payments received	9,881,000
Payments recouped	(2,214,000)
Balance	$ 7,667,000

Note 4 - Other Revenues (Details Textual)	3 Months Ended
Note 4 - Other Revenues (Details Textual)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Number of Skilled Nursing Centers	65
Insurance Services Revenue	$ 872,000	$ 1,048,000
Workers Compensation Revenue [Member]
Insurance Services Revenue	582,000	736,000
Professional Liability Insurance [Member]
Insurance Services Revenue	$ 290,000	312,000
National [Member]
Number of Skilled Nursing Centers	5
Property Management Fee Revenue	$ 1,320,000	$ 1,190,000
FLORIDA
Number of Skilled Nursing Centers	4

Note 4 - Other Revenues - Summary of Other Revenues (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Rental income	$ 5,959	$ 6,043
Management and accounting services fees	4,438	4,097
Insurance services	872	1,048
Other	84	368
Total other revenues	$ 11,353	$ 11,556

Note 5 - Non-operating Income (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Proceeds from Sale of Unconsolidated Company	$ 2,100,000	$ 2,100,000	$ 0
Gain (Loss) on Sale of Unconsolidated Company	$ 1,024,000	$ 1,024,000	$ (0)
Homecare Agency in Nashville, Tennessee [Member]
Equity Method Investment, Ownership Percentage				50.00%

Note 5 - Non-operating Income - Summary of Non-operating Income (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2024	Mar. 31, 2024	Mar. 31, 2023
Dividends and net realized gains and losses on sales of securities		$ 2,056,000	$ 1,233,000
Interest income		2,538,000	1,555,000
Equity in earnings of unconsolidated investments		67,000	1,535,000
Gain on sale of unconsolidated company	$ 1,024,000	1,024,000	(0)
Total non-operating income		$ 5,685,000	$ 4,323,000

Note 6 - Business Segments (Details Textual)	3 Months Ended
Note 6 - Business Segments (Details Textual)	Mar. 31, 2024
Number of Operating Segments	2

Note 6 - Business Segments - Summary of Financial Information by Reporting Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Net patient revenues	$ 285,823,000	$ 258,007,000
Other revenues	11,353,000	11,556,000
Net operating revenues	297,176,000	269,563,000
Costs and expenses:
Salaries, wages, and benefits	183,138,000	167,824,000
Other operating	77,429,000	71,489,000
Rent	10,348,000	10,092,000
Depreciation and amortization	10,586,000	10,048,000
Interest	46,000	98,000
Total costs and expenses	281,547,000	259,551,000
Income/(loss) from operations	15,629,000	10,012,000
Non-operating income (loss)	5,685,000	4,323,000
Unrealized gains on marketable equity securities	14,399,000	1,386,000
Income before income taxes	35,713,000	15,721,000
Inpatient Services Segment [Member]
Revenues:
Net patient revenues	252,254,000	226,169,000
Other revenues	15,000	271,000
Net operating revenues	252,269,000	226,440,000
Costs and expenses:
Salaries, wages, and benefits	150,890,000	138,939,000
Other operating	68,683,000	62,264,000
Rent	8,112,000	8,168,000
Depreciation and amortization	9,630,000	9,117,000
Interest	46,000	98,000
Total costs and expenses	237,361,000	218,586,000
Income/(loss) from operations	14,908,000	7,854,000
Non-operating income (loss)	0	0
Unrealized gains on marketable equity securities	0	0
Income before income taxes	14,908,000	7,854,000
Homecare Services Segment [Member]
Revenues:
Net patient revenues	33,569,000	31,838,000
Other revenues	0	0
Net operating revenues	33,569,000	31,838,000
Costs and expenses:
Salaries, wages, and benefits	21,009,000	20,244,000
Other operating	5,972,000	5,499,000
Rent	566,000	558,000
Depreciation and amortization	187,000	185,000
Interest	0	0
Total costs and expenses	27,734,000	26,486,000
Income/(loss) from operations	5,835,000	5,352,000
Non-operating income (loss)	0	0
Unrealized gains on marketable equity securities	0	0
Income before income taxes	5,835,000	5,352,000
Other Operating Segment [Member]
Revenues:
Net patient revenues	0	0
Other revenues	11,338,000	11,285,000
Net operating revenues	11,338,000	11,285,000
Costs and expenses:
Salaries, wages, and benefits	11,239,000	8,641,000
Other operating	2,774,000	3,726,000
Rent	1,670,000	1,366,000
Depreciation and amortization	769,000	746,000
Interest	0	0
Total costs and expenses	16,452,000	14,479,000
Income/(loss) from operations	(5,114,000)	(3,194,000)
Non-operating income (loss)	5,685,000	4,323,000
Unrealized gains on marketable equity securities	14,399,000	1,386,000
Income before income taxes	$ 14,970,000	$ 2,515,000

Note 7 - Long-term Leases (Details Textual)	3 Months Ended
Note 7 - Long-term Leases (Details Textual)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 34,351,000
Lessee, Operating Lease, Liability, to be Paid, Year Two	33,590,000
Lessee, Operating Lease, Liability, to be Paid, Year Three	24,933,000
Operating Lease, Expense	$ 10,348,000	$ 10,092,000
Two Leases with NHI [Member]
Number of Skilled Nursing Centers Leased from NHI	28
Number of Assisted Living Centers Leased from NHI	5
Number of Independent Living Centers Leased from NHI	3
Lease One With NHI [Member]
Number of Skilled Nursing Facilities Subleased	4
NHI Lease Agreement [Member]
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 32,625,000
Lessee, Operating Lease, Liability, to be Paid, Year Two	32,225,000
Lessee, Operating Lease, Liability, to be Paid, Year Three	31,975,000
Both NHI Lease Agreements [Member]
Operating Lease, Expense	$ 9,472,000	$ 9,295,000

Note 7 - Long-term Leases - Maturity of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
2025	$ 34,351
2026	33,590
2027	24,933
2028	493
2029	207
Thereafter	21
Total minimum lease payments	93,595
Less: amounts representing interest	(7,858)
Present value of future minimum lease payments	85,737
Less: current portion	(29,733)	$ (29,352)
Noncurrent lease liabilities	$ 56,004	$ 63,175

Note 8 - Earnings Per Share (Details Textual) - shares	3 Months Ended
Note 8 - Earnings Per Share (Details Textual) - shares	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	245,726	691,580

Note 8 - Earnings Per Share - Summary of Earnings and Weighted Average Number of Common Shares Used in Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Basic:
Weighted average common shares outstanding (in shares)	15,350,240	15,337,423
Net income attributable to National HealthCare Corporation	$ 26,213	$ 11,723
Earnings per common share, basic (in dollars per share)	$ 1.71	$ 0.76
Diluted:
Weighted average common shares outstanding (in shares)	15,350,240	15,337,423
Effects of dilutive instruments (in shares)	154,856	18,912
Weighted average common shares outstanding (in shares)	15,505,096	15,356,335
Net income attributable to National HealthCare Corporation	$ 26,213	$ 11,723
Earnings per common share, diluted (in dollars per share)	$ 1.69	$ 0.76

Note 9 - Investments in Marketable Securities (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Equity Securities Fv Ni Gross Unrealized Gain	$ 98,459,000		$ 84,514,000
Equity Securities Fv Ni Gross Unrealized Loss	474,000		928,000
Equity Securities, FV-NI, Unrealized Gain (Loss)	14,399,000	$ 1,386,000
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax	179,000		326,000
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	8,273,000		$ 7,937,000
Proceeds from Sale and Maturity of Marketable Securities	11,615,000	15,492,000
Debt Securities, Realized Gain (Loss)	$ 344,000	$ (492,000)

Note 9 - Investments in Marketable Securities - Marketable Securities and Restricted Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Unrestricted investments available for sale, equity, amortized cost	$ 24,734	$ 24,734
Marketable equity securities	123,040	111,117
Unrestricted investments available for sale, debt, amortized cost	132,410	135,338
Unrestricted investments available for sale, debt, fair value	124,316	127,727
Restricted marketable equity securities	29,616	26,779
Investments available for sale, amortized cost	187,081	189,648
Marketable Securities	276,972	265,623
Equity Securities [Member]
Unrestricted investments available for sale, equity, amortized cost	30,176	30,176
Marketable equity securities	123,040	111,117
Restricted investments available for sale, equity, amortized cost	24,495	24,134
Restricted marketable equity securities	29,616	26,779
Corporate Debt Securities [Member]
Unrestricted investments available for sale, debt, amortized cost	494	2,497
Unrestricted investments available for sale, debt, fair value	484	2,441
Restricted investments available for sale, debt, amortized cost	61,488	59,586
Restricted investments available for sale, debt, fair value	59,398	57,731
US Government Corporations and Agencies Securities [Member]
Unrestricted investments available for sale, debt, amortized cost	0	2,990
Unrestricted investments available for sale, debt, fair value	0	2,986
Restricted investments available for sale, debt, amortized cost	47,323	46,771
Restricted investments available for sale, debt, fair value	43,004	42,863
Asset-Backed Securities [Member]
Restricted investments available for sale, debt, amortized cost	19,026	19,388
Restricted investments available for sale, debt, fair value	17,438	17,659
US States and Political Subdivisions Debt Securities [Member]
Restricted investments available for sale, debt, amortized cost	4,079	4,106
Restricted investments available for sale, debt, fair value	$ 3,992	$ 4,047

Note 9 - Investments in Marketable Securities - Available for Sale Marketable Equity Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
NHI Common Stock, Shares (in shares)	1,630,642	1,630,642
NHI Common Stock, Cost	$ 24,734	$ 24,734
NHI Common Stock, fair value	123,040	111,117
NHI Common Stock [Member]
NHI Common Stock, fair value	$ 102,453	$ 91,071

Note 9 - Investments in Marketable Securities - Amortized Cost and Estimated Fair Value of Debt Securities as Available for Sale (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Within 1 year, cost	$ 21,299	$ 19,664
Within 1 year, fair value	20,785	19,328
1 to 5 years, cost	77,738	81,517
1 to 5 years, fair value	73,370	77,118
6 to 10 years, cost	32,012	33,515
6 to 10 years, fair value	28,925	30,802
Over 10 years, cost	1,361	642
Over 10 years, fair value	1,236	479
Cost	132,410	135,338
Fair Value	$ 124,316	$ 127,727

Note 10 - Fair Value Measurements - Summary of Fair Value Measurements by Level (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Restricted cash and cash equivalents	$ 27,150		$ 28,532
Available-for-sale securities (USD)	124,316	$ 127,727
Total financial assets	398,104
Corporate Debt Securities [Member]
Available-for-sale securities (USD)	484	2,441
Fair Value, Inputs, Level 1 [Member]
Total financial assets	359,403
Fair Value, Inputs, Level 2 [Member]
Total financial assets	38,224
Fair Value, Inputs, Level 3 [Member]
Total financial assets	477
Fair Value, Recurring [Member]
Cash and cash equivalents	93,982	107,076
Restricted cash and cash equivalents	27,150	18,892
Total financial assets		391,591
Fair Value, Recurring [Member] \| Equity Securities [Member]
Marketable equity securities	152,656	137,896
Fair Value, Recurring [Member] \| Corporate Debt Securities [Member]
Available-for-sale securities (USD)	59,882	60,171
Fair Value, Recurring [Member] \| Asset-Backed Securities [Member]
Available-for-sale securities (USD)	17,438	17,659
Fair Value, Recurring [Member] \| US Treasury Securities [Member]
Available-for-sale securities (USD)	43,004	45,850
Fair Value, Recurring [Member] \| US States and Political Subdivisions Debt Securities [Member]
Available-for-sale securities (USD)	3,992	4,047
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	93,982	107,076
Restricted cash and cash equivalents	27,150	18,892
Total financial assets		352,574
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| Equity Securities [Member]
Marketable equity securities	152,656	137,896
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| Corporate Debt Securities [Member]
Available-for-sale securities (USD)	42,611	42,860
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Available-for-sale securities (USD)	43,004	45,850
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Total financial assets		38,568
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Corporate Debt Securities [Member]
Available-for-sale securities (USD)	17,271	17,311
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Asset-Backed Securities [Member]
Available-for-sale securities (USD)	16,961	17,210
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| US States and Political Subdivisions Debt Securities [Member]
Available-for-sale securities (USD)	3,992	4,047
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Total financial assets		449
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| Asset-Backed Securities [Member]
Available-for-sale securities (USD)	$ 477	$ 449

Note 11 - Goodwill and Other Intangible Assets (Details Textual)	3 Months Ended
	Mar. 31, 2024 USD ($)
Goodwill and Intangible Asset Impairment, Total	$ 0
Acquisition of Caris [Member] \| Trade Names [Member]
Indefinite-lived Intangible Assets Acquired	4,340,000
Acquisition of Caris [Member] \| Certificates of Need and Licenses [Member]
Indefinite-lived Intangible Assets Acquired	$ 2,698,000

Note 11 - Goodwill and Other Intangible Assets - Activity Related to Goodwill By Segment (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Goodwill, balance	$ 168,295
Goodwill, additions	0
Goodwill, balance	168,295
Inpatient Services Segment [Member]
Goodwill, balance	3,741
Goodwill, additions	0
Goodwill, balance	3,741
Homecare and Hospice Segment [Member]
Goodwill, balance	164,554
Goodwill, additions	0
Goodwill, balance	$ 164,554

Note 12 - Stock Repurchase Program (Details Textual) - Common Stock [Member] - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock Repurchased and Retired During Period, Shares (in shares)	101,131	44,349
Stock Repurchased and Retired During Period, Value	$ 9,900,000	$ 2,482,000

Note 13 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 7,652,000
Salaries, Wages, and Benefits [Member]
Share-Based Payment Arrangement, Expense	$ 793,000	$ 639,000

Note 13 - Stock-based Compensation - Summary of Assumptions Used to Value Options Granted (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Risk–free interest rate	4.33%	4.52%
Expected volatility	24.10%	29.30%
Expected life (Year)	2 years 10 months 24 days	2 years 10 months 24 days
Expected dividend yield	2.64%	4.41%

Note 13 - Stock-based Compensation - Summary of Options Outstanding (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Options outstanding, shares (in shares)	588,534	445,144
Options outstanding, weighted average exercise price (in dollars per share)	$ 61.3	$ 66.62
Options granted, shares (in shares)	245,726	299,278
Options granted, weighted average exercise price (in dollars per share)	$ 94.07	$ 54.44
Options exercised, shares (in shares)	(137,874)	(103,481)
Options exercised, weighted average exercise price (in dollars per share)	$ 60.95	$ 64.72
Options cancelled, shares (in shares)		(52,407)
Options cancelled, weighted average exercise price (in dollars per share)		$ 60.58
Options outstanding, shares (in shares)	696,386	588,534
Options outstanding, weighted average exercise price (in dollars per share)	$ 72.93	$ 61.3
Options outstanding, aggregate intrinsic value	$ 15,025,015
Options exercisable, shares (in shares)	174,105
Options exercisable, weighted average exercise price (in dollars per share)	$ 68.48
Options exercisable, aggregate intrinsic value	$ 4,531,876

Note 13 - Stock-based Compensation - Options Outstanding by Exercise Price Range (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Options outstanding (in shares)	696,386	588,534	445,144
Options outstanding, weighted average exercise price (in dollars per share)	$ 72.93
Options outstanding, weighted average remaining contractual life (Year)	3 years 8 months 12 days
Exercise Price Range 1 [Member]
Options outstanding (in shares)	377,405
Options outstanding, exercise price, lower range (in dollars per share)	$ 53.94
Options outstanding, exercise price, upper range (in dollars per share)	69.19
Options outstanding, weighted average exercise price (in dollars per share)	$ 58.92
Options outstanding, weighted average remaining contractual life (Year)	3 years 6 months
Exercise Price Range 2 [Member]
Options outstanding (in shares)	318,981
Options outstanding, exercise price, lower range (in dollars per share)	$ 71.64
Options outstanding, exercise price, upper range (in dollars per share)	94.1
Options outstanding, weighted average exercise price (in dollars per share)	$ 89.51
Options outstanding, weighted average remaining contractual life (Year)	4 years

Note 14 - Income Taxes (Details Textual)	3 Months Ended
Note 14 - Income Taxes (Details Textual)	Mar. 31, 2024	Mar. 31, 2023
Effective Income Tax Rate Reconciliation, Percent	26.50%	28.20%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%

Note 15 - Credit Facility - Schedule of Long-Term Debt Instruments (Details Textual) - USD ($)	1 Months Ended
	May 31, 2023	Mar. 31, 2024
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Secured Overnight Financing Rate (SOFR) [Member]
Credit Facility [Member]
Debt Instrument, Face Amount	$ 50,000,000
Debt Instrument, Basis Spread on Variable Rate	1.25%
Debt Instrument, Basis Spread on Variable Rate, With Maintained Levels of Deposits	1.10%
Long-Term Debt, Gross		$ 0